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ABSTRACT 
Glioblastoma (GBM) is the most aggressive form of brain cancer. Despite today’s 
combinatory therapy consisting of surgery, radio- and chemotherapy, the prognosis remains 
dismal. Fostered by extensive tumor heterogeneity, cancer cell plasticity and the presence of 
cancer stem cells, GBM evades almost any therapeutic strategy, leading to high mortality. 
Thus, the development of novel therapies is of urgent need. 
With the identification of the Hallmarks of Cancer several cancer specific characteristics have 
been described that could serve as promising anti-cancer targets, including the combination of 
an elevated proliferation rate, crucial changes in cancer metabolism and consequently, an 
altered redox environment. Cancer cells and GBM in particular depend on effective anti-
oxidant defense systems and non-oncogenic addiction enzymes such as MTH1, an enzyme 
that detoxifies oxidized bases to prevent DNA damage and subsequent cell death.  
While potential anti-cancer targets are constantly being identified, the development of novel 
therapies against GBM is, amongst other reasons, hampered by the lack of orthotopic animal 
models that support large drug discovery screens. During the last decade, the zebrafish has 
been introduced as a clinically relevant model for human malignancies including cancer. 
Owing its biological and technical advantages, the zebrafish is the only vertebrate animal 
suitable for automated drug discovery screens to facilitate the identification and validation of 
novel cancer therapies.  
In this thesis, we primarily focused on complementing established biochemical and cellular 
assays with a broad application of the zebrafish model to: 
1. Describe factors that render cancer cells sensitive to MTH1 inhibitors 
2. Validate MTH1 as a target in GBM and GBM stem cells 
3. Develop a new orthotopic in vivo model for GBM  
In Paper I we have demonstrated that the cellular redox environment and activation of the 
hypoxia signaling axis determine sensitivity to MTH1 inhibition in vitro and in vivo, thus 
suggesting that MTH1 inhibition may present a promising approach to treat cancers 
characterized by deregulated hypoxia signaling and redox imbalance.  
In Paper II we have tested this hypothesis and showed that depletion or inhibition of MTH1 
efficiently reduces viability of patient-derived GBM cultures independent of aggressiveness 
ii 
in vitro and in vivo, thus providing supporting data that MTH1 represents a promising target 
for GBM therapy in particular.  
In Paper III we addressed the lack of an orthotopic animal model for GBM which is suitable 
for large drug discovery screens. We found that GBM cultures transplanted into the 
blastoderm of zebrafish embryos form a congregated tumor in the central nervous system, 
fully recapitulating the human disease. As no intracranial transplantation is required, we have 
developed an orthotopic animal model for GBM that could readily be implemented in fully 
automatable drug discovery screens in order to accelerate the identification and development 
of novel therapies against GBM.  
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 1 
1 INTRODUCTION 
Despite intensive research for novel anti-cancer therapies, cancer remains one of the leading 
causes of mortality worldwide. Although the incidence of cancer increases with behavioral 
risk factors and age, specific cancer types predominantly arise in children and young adults of 
a certain age, or dependent on ethnicity, gender, and region – showing that cancer can affect 
anyone. According to the World Health Organization (WHO), annual cancer cases are 
expected to rise from 14 million in 2012 to 22 million within the next two decades, 
underlining the urge to develop successful anti-cancer therapies
1
.  
1.1 THE NATURE OF CANCER  
Cancer summarizes a large group of diseases that can affect any part of the human body. It is 
generally thought that virtually all cells can transform into cancer cells. This transformation is 
a highly complex multistep process involving numerous alterations in molecular control 
mechanisms. Under physiological conditions, the cells in our body ensure tissue integrity and 
organ function by accurately balancing between cell proliferation and programmed cell death, 
so called apoptosis. However, genetic predisposition
1
 as well as environmental factors
2
, such 
as the exposure to radiation or toxins may facilitate the acquisition of mutations in our genetic 
code, also known as deoxyribonucleic acid (DNA), as well as changes in the epigenetic 
landscape. Some of these alterations induce the activation of oncogenes or the inactivation of 
tumor suppressor genes, which consequently disrupt the distinct balance between 
proliferation and apoptosis to promote abnormal tissue growth, or tumors. Generally, tumors 
can be benign or malignant. Benign tumors are localized and noninvasive, while malignant 
tumors are highly invasive as they grow beyond boundaries and spread through the 
circulatory system to invade distant organs and consequently, impair their function by 
forming metastases, the most deadly feature of cancer. 
All of the features a cell may gain upon malignant transformation by the activation of 
oncogenes and the inactivation of tumor suppressor genes are summarized as the Hallmarks 
of Cancer, including self-sufficiency in growth signals and limitless replicative potential, 
resistance to growth suppressors and apoptosis, genome instability and mutation, induction of 
angiogenesis, capability of tissue invasion and metastasis, alteration in energy metabolism 
and evasion of immune detection
3
 (Figure 1). These features clearly distinguish cancer cells 
from normal tissue and consequently affect the development of how we treat cancer.  
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Figure 1: The Hallmarks of Cancer  
This illustration presents an updated version of the Hallmarks of Cancer
4
. Due to a remarkable progress in cancer 
research the originally proposed hallmarks (sustaining proliferative signaling, evading growth suppressors, 
activating invasion and metastasis, enabling replicative immortality, inducing angiogenesis, resisting cell death) 
have been complemented with enabling characteristics (avoiding immune destruction, tumor-promoting 
inflammation, genome instability and mutation, deregulating cellular energetics), thus offering a variety of 
molecular targets for the development of anti-cancer drugs. Reprinted with permission from Elsevier, figure 
adapted from Hanahan and Weinberg, 2011.  
 
1.1.1 Cancer heterogeneity 
Recent advances in sequencing technologies and molecular diagnostics have helped 
researchers to understand the highly dynamic nature of cancer. Cancer cells display distinct 
genotypic profiles that determine cellular properties such as morphology, metabolism, 
proliferation, metastatic potential and sensitivity to therapy
5
. These genotypic profiles vary 
between different cancer types (inter-tumor heterogeneity) as well as among cancer cells 
within the same tumor (intra-tumor heterogeneity)
6
. Inter-tumor heterogeneity is closely 
related to intra-tumor heterogeneity, which can be explained by two different, but not 
mutually exclusive models.  
The “Clonal Evolution Model” implies that all cells in a tumor are biologically equivalent 
and potentially tumor initiating. As first described by Peter C. Nowell in 1976, cancers 
develop in a reiterative multistep process of clonal expansion by following the rules of 
Darwinian evolution
7
. The underlying mechanism of clonal expansion is the interplay of 
selectively advantageous “driver” mutations and selectively neutral “passenger” mutations 
 3 
with changes in the microenvironment
8
. While most genetic and epigenetic alterations are 
deleterious for cells, selectively advantageous genetic and epigenetic alterations induce 
critical phenotypical changes that enhance survival and allow for tumor growth initiation by 
occupying distinct tissue habitats
9
. However, due to increased genomic instability, these 
phenotypes are highly unstable and therefore prone to accumulate further genetic and 
epigenetic alterations. Consequently, new sub-clones with a selective advantage arise 
resulting in successive clonal expansions and hence, polyclonal outgrowth
7
 (Figure 2a). 
 
 
 
 
 
 
 
Figure 2: Models of tumor heterogeneity 
According to the “Clonal Evolution Model” most of the cells residing in a tumor acquire selectively 
advantageous mutations that enhance survival and promote tumor growth initiation (a). The “Cancer Stem Cell 
Model” indicates that aberrant growth seen in tumors originates from and is sustained by a mutated population of 
stem cells, which have the ability to self-renew and differentiate. Differentiated cancer cells gradually lose 
tumorigenicity (b).  
 
However, over the past decade, an increasing amount of data argued for the existence of 
tumor-initiating cells, often referred to as cancer stem cells (CSCs). According to the “Cancer 
Stem Cell Model” cancers are derived and maintained by a subset of highly tumorigenic 
CSCs, which are defined by their ability to self-renew and to differentiate into non-
tumorigenic progeny
10
. While inter-tumor heterogeneity depends on differences in the 
transformed stem cell of origin, intra-tumor heterogeneity reflects phenotypic differences 
induced by epigenetic alterations
11
 (Figure 2b).  
On a conceptual basis, it is more likely that aberrant growth seen in cancer originates from a 
mutated population of stem cells, which has lost normal homeostatic control on tissue 
development. Compared to other cell types, CSCs are considered to be suitable candidates for 
malignant transformation as they share similar features as normal stem cells such as self-
renewal capacity and a long life span. Since CSCs are able to escape the limits of 
a) b) 
4 
proliferation, they can accumulate genetic mutations over a long time
12
. These considerations 
suggest that malignant transformation arises due to oncogenic mutations in the stem cell 
compartment of normal tissues, resulting in unlimited proliferation and cancer. Evidence for 
the existence of CSCs and their tumorigenic potential was first demonstrated in leukemia 
13,14
 
and subsequently in solid tumors including breast cancer
15
 and glioblastoma
16
. 
The highly dynamic and unique genetic composition of individual cancers offers clinically 
significant challenges in terms of identifying suitable anti-cancer targets, thereby hampering 
the generation of effective treatment strategies
6
. Therefore, it is inevitable to understand the 
underlying mechanism of cancer cell propagation and the extent of its clonal architecture as 
early as possible. Taken together, both models offer valuable approaches to understand and 
characterize cancer heterogeneity leading to the development of refined treatment strategies.  
1.1.2 Hypoxia in cancer  
Generally, hypoxia describes a state of reduced oxygen tension that is potentially detrimental 
to aerobic organisms. In the context of cancer it refers to the situation where rapidly 
proliferating cancer cells outgrow their blood supply, consequently leading to the generation 
of areas with significantly lower oxygen concentrations than present in healthy tissues
17
. 
However, cells that reside in such hypoxic niches adjust their gene expression profile to the 
low oxygen supply through the pVHL-HIF1 system, the key mediator of oxygen 
homeostasis.  
The van Hippel-Lindau tumor suppressor protein (pVHL), an E3 ubiquitin protein ligase is 
responsible for regulating the oxygen-dependent stability of hypoxia-inducible factor 1 
(HIF1). HIF1 is a transcription factor regulating the expression of genes involved in 
angiogenesis, proliferation and survival as a response to low oxygen levels. It is a 
heterodimer consisting of two subunits, HIF1α and HIF1β. Subunit HIF1α is constitutively 
expressed under both normoxic and hypoxic conditions and localized in the cytoplasm
18,19
. 
In the presence of oxygen, HIF1α is rapidly degraded by oxygen and iron dependent prolyl 
hydroxylase domain enzymes (PHDs) which hydroxylate HIF1α at two prolyl residues. The 
hydroxylated form of HIF1α is recognized and bound by pVHL, which directs the attachment 
of a polyubiquitin chain and induces proteasomal degradation of the HIF1α subunit, thereby 
inhibiting its transcriptional activity
20
 (Figure 3).  
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However, in the absence of oxygen, PHDs are inactive and the hydroxylation of HIF1α 
proline residues is suspended. Consequently, subunit HIF1α is stabilized and translocates to 
the nucleus, where it forms the heterodimer HIF1 together with subunit HIF1β18,20,21. Upon 
binding to so called hypoxia response elements (HRE), which represent specific DNA 
binding sites of target genes, HIF1 activates the expression of hypoxia-inducible genes in 
order to adapt to hypoxic conditions
22
 (Figure 3).   
Based on the oxygen-dependent regulation of multiple essential signaling pathways involved 
in cell proliferation, survival as well as angiogenesis, hypoxic niches play a crucial role in the 
development and progression of cancer. It has been shown that hypoxia furthermore 
promotes cancer cell mobility, metastasis and therapy resistance by inducing epithelial-
mesenchymal transition (EMT)
17
 as well as maintenance of cell quiescence and self-renewal 
capacity as observed in CSCs
23
. In addition to that, increased HIF1 activity alters cellular 
metabolism by inducing a shift from normal energy metabolism to aerobic glycolysis
24
, 
which is further elaborated on in the following section.  
 
 
 
 
 
 
 
 
Figure 3: Prolyl hydroxylase domain-hypoxia-inducible factor (PHD-HIF) oxygen-sensing system 
In the presence of oxygen, HIF1α is hydroxylated at specific proline residues by PHD proteins, and thus 
recognized by pVHL which induces HIF1α ubiquitination and degradation by the proteasome. In the absence of 
oxygen, HIF1α is stabilized and translocates to the nucleus where it dimerizes with HIF1β to bind HREs, hence 
inducing the transcription of target genes. HIF1, hypoxia-inducible factor 1; PHD, prolyl hydroxylase domain; 
pVHL, von Hippel-Lindau protein; HRE, hypoxia response elements. Reprinted with permission from Elsevier, 
from Sugahara et al., 2017. 
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1.1.3 Metabolic changes in cancer 
In order to sustain essential molecular processes and biological functions, normal cells that 
experience aerobic conditions primarily produce energy upon full oxidation of glucose via 
oxidative phosphorylation in mitochondria. Under hypoxic conditions normal cells are 
limited to produce energy by breaking down glucose into lactate in the cytosol via 
(anaerobic) glycolysis
24
, which is also the main energy source in brain
25
, liver
26
 and muscle 
cells
27,28
. However, this process requires far more glucose while being energetically 
unfavorable as it produces only 5 % of glucose’s energy potential.  
In 1924, Otto Warburg discovered that cancer cells predominantly produce energy by an 
excessive conversion of glucose to lactate even in the presence of oxygen. This process is 
called aerobic glycolysis, or the “Warburg effect”29. Due to the fact that aerobic glycolysis is 
less efficient than oxidative phosphorylation in terms of adenosine triphosphate (ATP) 
production, cancer cells’ preference for aerobic glycolysis remained questionable. While 
Warburg himself postulated that the change in metabolism is the fundamental cause of 
cancer
30
, current explanations rather indicate that it is the ultimate consequence of malignant 
transformation such as an adaptation to deficient oxidative phosphorylation in damaged 
mitochondria or to hypoxic areas, as mentioned earlier. However, as this does not explain 
why cancer cells rely on aerobic glycolysis in the presence of oxygen, the metabolic change 
may also be associated with rapid cell growth as glycolysis increases the generation of 
metabolites required in proliferating cells
31
. Therefore, it has been postulated that the 
metabolism of cancer cells, similarly to proliferating cells in general, has adapted to rapid cell 
growth by facilitating both uptake and incorporation of nutrients into the biomass
32
. Along 
with this hypothesis, it has been shown that numerous oncogenes which are activated in 
cancer cells such as phosphoinositide-3-kinase (PI3K), Myc and Ras are linked to both 
growth control and glucose metabolism i.e. by regulating the expression of glucose 1 
transporter (GLUT1) on the cell membrane and hence, the influx of glucose that is 
subsequently converted via aerobic glycolysis
33
.  
While the precise biological reason for the Warburg effect remains unknown, the most 
reasonable explanation for the metabolic change seen in cancer cells is the constant 
generation of building blocks for new cancer cells. However, the price cancer cells have to 
pay for this metabolic switch in order to maintain constantly high growth rates is reflected in 
an altered redox balance
34
, which is discussed in the following section.  
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1.2 REDOX HOMEOSTASIS 
1.2.1 Redox balance and redox signaling 
Reactive oxygen species (ROS) such as hydrogen peroxide (H2O2) and superoxide (O2-), 
which can be produced unintentionally as unavoidable side products of aerobic metabolism or 
intentionally by various enzymatic systems, constitute the redox environment of a cell. Under 
physiological conditions, cells have comprised highly efficient scavenging systems to balance 
the production and elimination of ROS and thereby, maintain redox homeostasis.  
When present in low levels, these reactive molecules regulate cellular signaling pathways that 
are involved in cell proliferation, differentiation and survival
35
. Amongst others, central 
transcription factors including anti-oxidant major regular Nrf-2 (nuclear-factor (erythroid-
derived 2)-like 2)
36
, HIF1α21 and NF-κB (nuclear factor kappa-light-chain-enhancer of 
activated B cells)
37
 are known to be redox regulated. Interestingly, most transcription factors 
underlying redox regulation are closely associated with cancer. Major targets for redox 
signaling are cysteines as they present a unique target for the reversible oxidation/reduction 
of their residues
38
. Following oxidation, cysteines form intra- or intermolecular disulfide 
bonds, which may alter protein structure and thereby regulate co-factor binding or 
dimerization. Additionally, they can be glutathionylated resulting in the regulation of 
enzymatic activity
39,40
. 
However, due to their high chemical reactivity, excessive ROS levels can damage cellular 
proteins, lipids as well as nuclear and mitochondrial DNA leading to cellular senescence, 
apoptosis and carcinogenesis
41,42
. 
1.2.2 Redox balance in cancer  
Both an altered redox homeostasis and deregulated redox signaling present generally 
accepted hallmarks of cancer cells. Following the initiation of tumorigenesis by exposure to 
radiation or carcinogens, the acquisition of genetic, metabolic and microenvironment-
associated alterations lead to persistently upregulated ROS levels
43
. In order to survive, 
cancer cells compensate these high intrinsic oxidative stress levels by increasing their anti-
oxidant capacity
44–46
, thereby shifting the overall redox balancing point upwards 
(Figure 4a)
43
. Paradoxically, this adaptation further promotes tumor growth by generating 
additional DNA damage and genomic instability
47
. However, simply increasing ROS levels 
to induce cancer cell death remains insufficient, which is likely due to the high plasticity of 
the oncogenic redox system
48
 and its efficient mechanisms of ROS detoxification, promoting 
8 
growth under oxidizing conditions. Therefore, disabling the ROS defense system by targeting 
anti-oxidant or other non-oncogenic addiction enzymes has become a promising area of 
research (Figure 4b) 
46,49
.   
1.2.3 DNA integrity and oxidative damage in cancer  
The genetic information of all living organisms, including humans, is enclosed in the DNA, 
or deoxyribonucleic acid, where it is stored as a code consisting of four chemical bases, the 
purine bases adenine (A) and guanine (G) as well as the pyrimidine bases cytosine (C) and 
thymine (T). Similar to letters in the alphabet, the order of these bases determines protein 
composition and hence, all information for building an organism and maintaining its 
multicellular functionality. Each DNA base can be supplemented with a sugar molecule to 
form a nucleoside, or with a sugar and phosphate molecules to form a nucleotide. For the 
incorporation into the DNA, purine bases always pair up with pyrimidine bases (A:T and 
G:C) to build up a complementary nucleotide double helix, the unique structure of our 
DNA
50
.  
As described by Nobelist Thomas Lindahl in 1993, the chemical stability of our DNA is 
constantly challenged by numerous endogenous and exogenous substances that cause DNA 
lesions via methylation, hydrolysis and oxidation
51
. Such lesions can be recognized by 
complex DNA protection and repair mechanisms to maintain genomic integrity and cellular 
fitness. However, misrepair of potentially lethal lesions may result in disturbed expression of 
oncogenes and tumor suppressor genes leading to malignant transformation and 
carcinogenesis. 
Among other macromolecules in the cell, the DNA represents the major target of highly 
reactive ROS molecules. Aside from the nucleotide double helix, it is well established that 
the free deoxyribonucleoside triphosphate pool (dNTP) is especially prone to oxidative 
damage
41
. Among all nucleotides, deoxyguanosine triphosphate (dGTP) is most prevalently 
oxidized upon exposure to ROS due to its favorable chemical structure. Its product, 8-oxo-
7,8-dihydroxy-2’-deoxyguanosine-5’-triphosphate (8-oxo-dGTP), can readily be incorporated 
into the DNA causing mutagenic G:C to T:A and vice versa transversions, subsequently 
leading to genomic instability and cell death
52,53
. 
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Figure 4: Targeting redox alterations in cancer 
In order to survive and proliferate, cancer cells display a highly plastic redox environment and adapt to elevated 
ROS pressure by increasing their anti-oxidant ability, thereby shifting the overall redox balancing point upwards 
(a). As cancer cells depend on ROS elimination systems to ensure growth under oxidizing conditions while 
keeping ROS levels below the toxic threshold, they are more vulnerable to further oxidative insults. Hence, 
stimulating ROS generation and targeting ROS elimination system offers therapeutic selectivity to fight against 
cancer cells. Ideally, the simultaneous exposure to ROS-generating agents and compounds that interfere with 
cellular anti-oxidant systems may induce additive or synergistic effects to promote ROS-induced damage and 
subsequent cancer cell death (b). ROS, reactive oxygen species. Reprinted with permission from Springer 
Nature, from Trachootham et al., 2009. 
b) 
a) 
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1.2.4 MTH1, a sanitizing enzyme  
As indicated before, for the maintenance of genomic integrity and cellular fitness, cells 
comprise complex and highly efficient DNA protection and repair mechanisms. Protection 
mechanisms include nucleotide sanitation enzymes that prevent the incorporation of 
deleterious bases into the DNA by promoting their immediate elimination
54
. However, if the 
amount of erroneous nucleotides outweighs the house-cleaning capacity of sanitation 
enzymes, first line protection mechanisms fail rendering the incorporation of damaged bases 
into DNA inevitable. For this case, cells have developed a variety of repair mechanisms 
including base excision repair (BER)
55
 and the mismatch repair (MMR) machinery
56
 to detect 
and excise deleterious bases. 
Focusing on DNA protection mechanisms, the most common sanitation enzymes have been 
described as members of the nucleoside diphosphate linked to some other moiety X (NUDIX) 
hydrolase family
57
. Despite sequential and structural differences among the 22 family 
members described in humans, all members share a distinct amino acid NUDIX box domain, 
which determines their function: catalyzing the hydrolysis of nucleoside-like di- or 
triphosphate to respective monophosphates
58,59
. The variety of substrate preferences among 
NUDIX family members is linked to structural differences, respectively
59
. 
Human NUDIX hydrolase NUDT1 (NUDIX type 1), also known as human mutT homolog 1 
(MTH1) has recently been identified as a sanitation enzyme in cancer cells
60,61
. Due to the 
altered redox homeostasis and increased oxidative pressure, cancer cells rely on efficient anti-
oxidant systems and other non-oncogenic addiction enzymes, such as MTH1. It has been 
shown that the MTH1 enzyme sanitizes the oxidized dNTP pool by hydrolyzing 8-oxo-dGTP 
and 2-OH-dATP (2-hydroxy-2’-deoxyadenosine-5’-triphosphate) to their respective 
monophosphates
61
, thereby preventing incorporation of these erroneous nucleotides into 
DNA and potentially lethal consequences
49
 (Figure 5).  
Recently, we and others have extensively described MTH1 as a promising anti-cancer 
target
49,62–65
. Our group was able to show that depletion of MTH1 either by siRNA-mediated 
knockdown or exposure to in-house developed MTH1 small molecule inhibitors induces 
cancer-specific DNA damage and subsequent cancer cell death in vitro and in vivo
49,64
 
(Figure 5a), while having minor effects on normal cells. In 2016, the role of MTH1 in cancer 
was challenged, since some small molecule MTH1 inhibitors were not cytotoxic despite 
inhibiting the MTH1 enzymatic activity in vitro
66–68
. Following extensive research to further 
understand the mechanism of action of our potent and cytotoxic MTH1 inhibitors, we now 
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know that they act via a dual mechanism to induce cell death by A) causing a mitotic arrest, 
which further induces production of ROS and 8-oxo-dGTP and B) inhibition of 8-oxo-
dGTPase activity resulting in elevated incorporation of oxidized nucleotides into DNA 
(Figure 5b) (unpublished data). 
Here, we determine the characteristics that render cancer cells sensitive to MTH1 inhibition. 
Based on the close relation to an elevated redox environment present in cancer cells, it is 
moreover inevitable to study the effect of MTH1 inhibition in highly aggressive and 
treatment-resistant glioblastomas, which suffer tremendous oxidative pressure. 
 
 
 
 
 
 
 
 
 
Figure 5: MTH1 inhibition as a promising anti-cancer therapy 
As originally proposed, inhibition of sanitizing enzyme MTH1 leads to the incorporation of oxidized nucleotides 
into DNA and hence, induction of DNA damage with subsequent cancer cell death (a). According to the updated 
mechanism of action, cytotoxic MTH1 inhibitors interfere with tubulin dynamics, which arrest cells in mitosis 
and cause an increase in ROS, specifically in cancer cells. High levels of ROS oxidize the nucleotide pool to 
form oxidized deoxynucleoside triphosphates, such as 8-oxo-dGTP and 2OH-dATP. Additionally, cytotoxic 
MTH1 inhibitors prevent MTH1-mediated clearance of 8-oxo-dGTP and 2-OH-dATP, which results in Polκ- or 
Polβ-mediated incorporation of 8-oxo-dGTP and 2-OH-dATP into DNA, thereby causing DNA damage and cell 
death (b). MTH1, MutT homolog 1; MTH1i, MTH1 inhibitors; DNA, deoxyribonucleic acid; ROS, reactive 
oxygen species; 8-oxo-dGTP, 8-oxo-7,8-dihydroxy-2’-deoxyguanosine-5’-triphosphate; 2-OH-dGTP, 2-
hydroxy-2’-deoxyadenosine-5’-triphosphate; Polκ, polymerase κ; Polβ, polymerase β. Reprinted with permission 
from Springer Nature, from Gad et al., 2014. 
 
 
 
 
 
b) a) 
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1.3 GLIOMA AND GLIOBLASTOMA 
Gliomas represent the most common tumors of the central nervous system (CNS) and are 
classified into clinical grades of ascending malignancy based on histopathological criteria by 
the WHO
69
. Grade IV gliomas, namely glioblastoma multiforme (GBM), are the most 
malignant and aggressive primary brain tumors displaying the worst prognosis with only 
10 % of diagnosed patients surviving 5 years
70
. 
Over the past decade, scientists have discovered various genetic mutations and abnormalities 
in different pathways promoting the disease progression of GBM. Occurring in 60 - 90 % of 
all GBM cases, loss of heterozygosity (LOH) on chromosome arm 10q represents the most 
frequent gene alteration in GBM
71
. Common genetic abnormalities include i.e. epidermal 
growth factor receptor (EGFR) amplification
72
 as well as mutations in tumor suppressor 
genes p53 and PTEN (phosphatase and tensin homolog)
73,74
. As the disease progresses, 
additional genetic alterations can be found. Some of the genetic alterations present in GBM 
are currently targeted for therapeutic use. However, identifying an optimal target is hampered 
by the fact that GBMs are composed of a highly heterogeneous mixture of tumor cells
75
. On 
top of that, high cellular plasticity promotes the dedifferentiation of tumor cells into a more 
stem cell-like state
76
. Until today, multiple studies support the theory of a prominin-1 
(CD133)
+ 
stem cell population in GBM, which is responsible for both maintenance of a tumor 
and tumor recurrence after therapy
16
. Strongest evidence for the existence of CSCs is 
provided by generating a phenocopy of the original patient’s tumor in vivo upon 
transplantation of CD133
+ 
but not CD133
- 
cells into immunodeficient mice. Most recently, 
researchers have found heterogeneous CSC sub-clones exhibiting dissimilar phenotypes 
regarding morphology, self-renewal, proliferative capacities and therapeutic sensitivities
76
, 
thereby further hampering the identification of a common target.  
1.3.1 Standard therapy of care 
Currently, the standard treatment of brain tumors consists of surgical resection, radiotherapy 
and adjuvant chemotherapy. Depending on the individual tumor size and shape, its location in 
the brain and surrounding blood vessels, surgeons choose between gross total resection 
(GTR) and subtotal resection (STR). Tumor-specific fluorescent staining such as 5-
aminolevulinic acid (ALA) enables precise distinction between tumor and non-tumor cells in 
order to facilitate maximal resection of the malignant tumor mass
77
. Remaining tumor cells 
are targeted by subsequent radiotherapy, which induces DNA damage, most prevalently 
double-strand breaks (DSB), leading to apoptosis. Resistance mechanisms are usually 
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conferred by upregulated DSB repair machinery rendering tumor cells insensitive to 
radiotherapy
78
. The standard adjuvant chemotherapy against GBM is Temozolomide (TMZ), 
a prodrug that is able to pass the blood-brain barrier (BBB). Once converted to the active 
form, the alkylating agent MTIC (5-(3-methyltriazen-1-yl)imidazole-4-carboxamide), it 
methylates purines in the DNA
79
. If left unrepaired, these lesions induce tumor cell death. 
However, it has been shown that the sensitivity to TMZ correlates with the methylation state 
of the O
6
-methylguanine-DNA-methyltransferase (MGMT) promoter in tumor cells. 
Epigenetic silencing of the MGMT gene results in low intracellular concentrations of 
MGMT, thereby increasing the sensitivity to TMZ and promoting tumor cell death
80
. 
To sum up, the therapeutic inefficacy of TMZ in GBM cells with high cellular concentrations 
of MGMT combined with the risk of possible side-effects such as TMZ-induced DNA 
damage in healthy cell highlight the urge to improve GBM therapy regarding efficacy and 
specificity.  
1.3.2 Alternative treatment options 
All together the combination of surgical resection, radiotherapy and adjuvant chemotherapy 
with TMZ has improved the average patient survival of 12.1 months to 14.6 months
81
. Other 
Food and Drug Administration (FDA)-approved drugs against GBM show similar modest 
effects such as anti-angiogenic drug Avastin (Bevacizumab)
82,83
 and Lomustine, either alone 
or in combination
84
. 
Today’s treatment options remain insufficient as patients suffer tumor recurrence due to 
inherent or acquired resistance mechanisms within 6 month after resection
70
. Additionally, 
GBMs are composed of a highly heterogeneous mixture of tumor cells with unique 
mutational profiles
75
. Therefore, there is an urgent need to fully understand the complex 
tumor biology of gliomas and GBM in specific in order to circumvent resistance mechanisms 
and identify new targets for effective clinical treatments.  
Currently, various clinical studies investigate the safety and efficacy of novel therapeutic 
approaches including monoclonal antibodies
85
, oncolytic viruses
86
 and small molecules to 
inhibit cancer cell specific signaling pathways
87 
or to reprogram the innate immune system
88
. 
Some of these clinical candidates are described as follows.  
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AG-120 
Amongst other pro-oncogenic events, it has been shown that isocitrate dehydrogenase (IDH)-
1 mutations initiate and drive cancer growth, thereby promoting the transition from low-grade 
gliomas to secondary GBM
89
. Point mutations in the active site of IDH-1 reduce the efficacy 
to convert isocitrate to alpha-ketoglutarate and simultaneously promote the ability to convert 
alpha-ketoglutarate to 2-hydroxyglutarate (2-HG), an onco-metabolite, which is believed to 
cause epigenetic changes that block normal differentiation of cells
90
. This block could be 
reversed by inhibiting mutated IDH-1, which results in low levels of 2-HG
91
. Thus, mutated 
IDH-1 represents a new therapeutic target to fight against GBM. Supported by promising 
results in preclinical in vivo
91
 and clinical phase I studies
92
 further clinical evaluations for 
AG-120, the first-in-class mutant IDH-1 inhibitor are warranted. 
Dovitinib  
As tyrosine kinases represent fundamental mediators of various signaling cascades involved 
in growth, differentiation, metabolism and apoptosis, it is generally accepted that mutation-
based tyrosine kinase malfunctions may lead to oncogenic activation and thus, cancer 
initiation and progression. Recently, selective tyrosine kinase inhibitors have shown 
promising therapeutic effects, such as Imatinib as a treatment against Philadelphia 
chromosome-positive chronic myeloid leukemia (CML). Dovitinib, however, is a multi-
tyrosine kinase inhibitor that targets several tumor-relevant tyrosine kinases including FGFR 
(fibroblast growth factor receptor), VEGFR (vascular endothelial growth factor receptor), 
PDGFRß (platelet derived growth factor receptor ß) and c-kit (receptor tyrosine kinase kit). 
As an increased activity of those tyrosine kinases is closely associated with GBM 
oncogenesis, multi-tyrosine kinase inhibition could be an effective treatment approach
93
. 
Dovitinib, which is able to cross the BBB, has recently been tested in phase I trials in patients 
with recurrent GBM
93
. 
Palbociclib 
Pfizer has developed PD0332991 (Palbociclib), a cyclin-dependent kinase (CDK) 4/6 
inhibitor, to treat patients with advanced estrogen receptor-positive and human epidermal 
growth factor receptor (HER) 2-negative breast cancer. The inhibition of CDK 4/6 leads to 
the blockage of retinoblastoma 1 (RB1) phosphorylation and consequently cell cycle arrest. 
As GBM exhibits similar alterations in the cyclin D1-CDK 4/6-RB1 pathways, Palbociclib 
represents a promising drug for the treatment of GBM
94
. First results indicate sensitivity of 
GBM cell lines to Palbociclib in vitro. However, the drug only seems to inhibit cell 
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proliferation in Rb1 proficient GBM cells, while RB1 deficient cells are resistant
95
. Further 
studies confirm the anti-proliferative effect of Palbociclib in vivo along with a survival 
benefit
96
. The clinical potential of Palbociclib against GBM has recently been tested in 
phase II trials in patients with Rb1 positive, recurrent GBMs. In this trial, Palbociclib has not 
been effective against recurrent GBM of a heavily pretreated patient population, and further 
exploration targeting the CDK 4/6 pathway is required
97
. 
Valganciclovir 
Gene products of the human cytomegalovirus (HCMV) are known to dysregulate multiple 
signaling pathways involved in the oncogenesis of several cancer types
98
. Among other 
dysregulations, HCMV proteins are believed to control cell cycle progression by interacting 
with p53, Rb1 and cyclins, inducing chromosomal and DNA damage as well as inhibiting 
DNA repair and apoptosis
99
. As a high percentage of malignant glioma is infected by HCMV, 
therefore expressing multiple HCMV gene products, it is suggested that HCMV plays an 
important role in glioma pathogenesis
98
. Indeed, both HCMV replication and tumor growth 
are inhibited in vitro and in animal xenografts of tumors that are HCMV-positive in vivo 
using Valganciclovir
100
, an anti-viral agent and prodrug of Ganciclovir. In a clinical trial, the 
combination of Valganciclovir to the standard therapy showed an increased survival 
benefit
101
. As only tumor cells are HCMV-positive, while the healthy surrounding tissue 
remains HCMV-negative, high treatment specificity is rendered, hence decreasing the risk of 
side-effects
99
. Supported by preliminary clinical data
102
, further studies are recommended to 
investigate the effect of Valganciclovir in GBM patients.  
1.3.3 Current animal models for glioblastoma  
In order to enhance our knowledge on gliomas and GBM in specific, and to fully understand 
the complexity of molecular mechanisms underlying brain tumor initiation and progression, 
the use of animals as preclinical models is inevitable. Currently available in vivo models for 
primary brain tumors can be summarized in three categories including a variety of chemically 
induced models
103,104
, xenograft models
105,106
 and genetically engineered mouse (GEM) 
models
107
, all extensively reviewed in numerous publications
108–110
 (Figure 6). Despite the 
fact that none of these in vivo models fully recapitulates the development and progression of 
human brain tumors, all of them have made significant contributions to the understanding of 
brain tumor biology. 
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Both chemically induced and GEM models benefit from an intact immune system while 
mimicking cancer initiation and progression from early stages on, hence providing a useful 
tool to investigate the molecular mechanisms of carcinogenesis within the CNS and to 
develop targeted therapeutics
111
. Xenograft models, which are based on the orthotopic 
transplantation of either patient-derived glioma cells or fresh brain tumor biopsy spheroids 
into immunodeficient mice, closely resemble the genetic and phenotypic heterogeneity of the 
original patient tumor
112
. Due to their high clinical relevance, xenograft models remain the 
gold standard in terms of performing safety and efficacy studies of novel drugs before 
registration by the FDA.  
However, while recapitulating human brain tumors sufficiently well, all of these in vivo 
models come along with high cost and time-consumption as well as technical limitations and 
ethical burden, rendering them inapplicable for large drug screen projects to identify novel 
therapeutic targets against GBM. 
 
Figure 6: Overview on preclinical in vivo models for brain tumors in rodents 
Currently available preclinical in vivo models for brain tumors are generated by three approaches including 
1) chemically induced models, 2) genetically engineered models and 3) orthotopic models. Each category 
comprises a large variety of different models and while having contributed significantly to a better understanding 
of brain tumors initiation and progression, none of these models is applicable for large scale drug screens.  
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1.4 THE ZEBRAFISH AS A MODEL ORGANISM 
1.4.1 Application in cancer research 
During the last decades, the zebrafish (Danio rerio) has become a powerful animal model to 
study vertebrate development
113
, integrative physiology
114
 and toxicology
115
. More recently, 
the zebrafish emerged as a preclinical model for various cancer types, including liver
116
 
melanoma
117 
and leukemia
118
. Compared to rodent models, advantages such as cost efficient 
husbandry, breeding of large embryo numbers, rapid development and small 
size/transparency of embryos render this model suitable for high-throughput drug screen 
projects
119,120
. In addition to that, the absence of a functional adaptive immune system up to 
4 - 6 weeks post fertilization facilitates the microinjection of human primary tumor material 
into zebrafish embryos, thereby increasing the clinical relevance of the model by 
recapitulating heterogeneity of the original patient tumor. 
1.4.2 Advantages and limitations of the zebrafish model  
Due to numerous technical and biological advantages (Table 1), the zebrafish has emerged as 
a powerful model organism for preclinical studies involving numerous human diseases 
including neurological disorders
121–123
 as well as cancer
116–118
. 
Technical advantages include cost efficient husbandry, large number of offspring, rapid 
ex utero development as well as small size and transparency of embryos (< 48 hours post 
fertilization, hpf) which render the zebrafish a suitable model for high-throughput drug 
discovery screens
120,124
. Additionally, the zebrafish genome has been fully sequenced and 
numerous, well-characterized zebrafish strains are readily available. These include transgenic 
zebrafish strains like the casper mutant lacking complete pigmentation
125
 or fluorescent 
reporter strains demarking distinct cell types such as epithelial cells in blood vessels
126
 and 
numerous hematopoietic cells like T cells and macrophages
127,128
. Taken together, the 
availability of such transgenic fluorescent reporter stains allows for minimally invasive 
imaging techniques such as real-time imaging via light-sheet microscopy to study cell-cell 
interactions on a singular cell level.  
Further biological advantages include high genetic similarity to humans enhancing the 
model’s value for preclinical studies. Zebrafish are vertebrates and share a high degree of 
sequential and functional homology with mammals, and in particular humans, conferring to 
the conservation of countless cell biological and developmental processes
129,130
. Despite the 
phylogenetic distance between teleost fish and mammals, the zebrafish holds 82 % of human 
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disease-causing genes, thereby providing useful insights into various disease progressions
120
. 
Compared to simple cell culture systems, the zebrafish offers a broader range of disease-
related phenotypes that can be simply monitored in phenotypic screens including vital 
parameters, pain, vascular tone, and tumor metastasis and gut motility
120
. In addition to that, 
recent advances in genome editing techniques including transcription activator-like effector 
nucleases (TALEN) or clustered regularly interspaced short palindrome repeats (CRISPR) 
and CRISPR-associated systems (Cas) allow for easy introduction of genetic modification 
that mimic oncogenic mutation profiles and drive tumor progression
131,132
, thereby creating 
an efficient strategy for target-based drug discovery.  
Table 1: Summary of advantages and limitations using zebrafish as a model for drug screens   
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By contrast, the immature state of the immune system represents a rather double-edged 
feature in developing zebrafish embryos. While the innate immune system is functional by 
3 days post fertilization (dpf), the adaptive immune system develops around 4 - 6 weeks post 
fertilization
133,134
. On the one hand, the immature immune system averts the use of immune 
suppressing agents prior to transplantation of cancer specimen
135
, a prerequisite for 
xenotransplantation of patient material. On the other hand, it limits studies focusing on the 
interplay between transplanted cancer cells and the immune system and how treatment 
efficacy is affected, as it may not reproduce the behavior of cancer in a fully 
immunocompetent host. Due to phylogenetic distance between teleost fish and mammals, 
including humans, the zebrafish offers a different microenvironment to transplanted human 
cancer cells. This becomes a problem when orthotopic transplantation is impossible due to 
the lack of corresponding organs in zebrafish
136
. Moreover, cancer predominantly arises 
during adulthood and cancer cells may display altered phenotypes upon transplantation into 
the embryonic environment of developing zebrafish
124
. However, it has been shown that 
numerous signaling pathways underlying embryonic development are reactivated during 
malignant transformation
137–139
. With that in mind, further studies are needed to fully 
understand the potential influence the embryonic zebrafish environment may have on 
transplanted cancer cells.  
1.4.3 Zebrafish models for glioblastoma  
Glioblastoma is the most aggressive form of primary brain tumors and despite combinatory 
treatments, tumor recurrence and patient death are inevitable
81
. The development of novel 
strategies to fight against this deadly disease is challenged by the lack of orthotopic animal 
models for GBM that are suitable for high-throughput drug screens. Due to its beneficial 
features listed before, the zebrafish represents a powerful platform for preclinical and drug 
discovery research
120,140
. 
Until today, several research groups have used the zebrafish to create either orthotopic or 
automatable xenograft models of GBM. For the latter one, researchers have injected primary 
GBM cells into the protruding yolk sac serving as a nutritional cache for developing zebrafish 
embryos to study tumor growth and invasion
141,142
. More recently, chemically induced rat 
GBM cells were injected into the yolk sac to study the effect of nitric oxide on tumor 
development
143
. Despite the fact that automatable injection comprises a major requirement 
for large drug screen projects, the disease-recapitulating quality of the zebrafish yolk sac as a 
non-orthotopic injection site remains questionable (Figure 7). 
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Figure 7: Comparison of zebrafish injection sites  
Currently available zebrafish models for glioblastoma are generated by using two different injections sites, the 
brain and the yolk sac. While transplantation of GBM cultures directly into the brain is clinically relevant, 
though laborious, the disease-recapitulating capacity of the yolk sac remains questionable. Here, we introduce a 
novel transplantation technique to generate an orthotopic, and thus, clinically relevant zebrafish model for GBM, 
which is applicable for drug discovery screens.  
 
In contrast to automatable xenograft models, other research groups have generated orthotopic 
zebrafish models for GBM to investigate angiogenesis, invasion and the role of signaling 
pathways in GBM cell differentiation
144
. More recently, one group orthotopically 
transplanted isolated pediatric mouse brain tumors and GBM cells, which retained 
histological characteristics of the tumor of origin, thereby creating an intermediary platform 
between high-throughput drug screens and mouse models
145
. Another group orthotopically 
transplanted patient-derived GBM cell cultures and neurospheres leading to progressive and 
heterogeneous brain tumor growth and increased lethality. Treatment of these tumors with 
TMZ resulted in a tumor size reduction in vivo and an increase of survival
146
 (Figure 7). 
These studies highlight the potential of the zebrafish model to serve as a clinically relevant 
screening platform to facilitate brain cancer drug discovery. 
However, since the disease-recapitulating capacities of automatable, though non-orthotopic 
zebrafish models for GBM remain questionable and the generation of orthotopic zebrafish 
models for GBM is rather labor-intensive and not automatable as transplantation procedures 
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require sedation and precise positioning of the zebrafish as well as highly skilled personnel, a 
novel model circumventing these limitations is of high interest. 
The optimal orthotopic zebrafish model for GBM should be suitable for fully automated 
high-throughput drug screens, including automatable tumor transplantation, embryo handling, 
drug exposure and read-out processes. 
1.4.4 Clinical relevance 
Despite numerous technical and biological advantages that render the zebrafish a highly 
attractive model system for phenotypic high-throughput drug discovery screens, questions 
about its clinical relevance to humans remain of central importance. 
Although being an aquatic, ectothermic organism with anatomical differences compared to 
humans, genome sequencing has revealed that the zebrafish contains orthologues of 71 % of 
all human proteins including 82 % of disease-causing proteins
129
. In relation to that, it has 
been shown that protein targets of the ten most-prescribed drugs have zebrafish orthologues 
with sequence identity ranging from 54 % (glucocorticoid receptor) to 91 % (thyroid 
receptor)
120
 (Figure 8). As the sequence similarity is greater in the active side of enzymes, 
the pharmacological effect is still highly conserved in the zebrafish. Moreover, despite 
adaptations to the aquatic life, zebrafish physiology is well-conserved and exhibits many 
similarities to humans such as the hematopoietic system
147
, glucose metabolism
148
 and the 
cardiovascular system
149
. Intriguingly, the human cardiac electrophysiology shows greater 
similarity to zebrafish than to rodents (Figure 8). To date, numerous cardiac disease models 
could be recapitulated in zebrafish including drug treatments showing the same 
pharmacological effects as in humans
149–152
. 
In regard to cancer, transgenic zebrafish models are of high clinical relevance as they allow 
investigation of cancer initiation and progression, induction of angiogenesis and metastasis as 
well as interactions with host cells such as the immune system. For example, the first study 
ever to investigate the effect of activated oncogene BRAF in melanoma development in an 
animal model was performed using zebrafish
153
. In this landmark study, transgenic zebrafish 
expressing the most common BRAF mutant form V600E under the control of melanocyte 
mitfa promoter showed increased patches of ectopic melanocytes. In addition to that, the 
induction of melanocyte lesions in p53-deficient zebrafish led to the development of highly 
invasive melanomas
153
. Following this study, further transgenic zebrafish models for multiple 
cancer types such as neuroblastoma
154
, brain cancer
155
 and leukemia
156
 were established 
allowing to investigate cancer driving mechanisms and thereby, significantly contributing to 
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our knowledge of cancer biology. In addition to that, numerous zebrafish cancer studies 
involving xenotransplantation of patient-derived cancer cells such as breast cancer
157
 and 
glioblastoma
146
 were established and further confirm the clinical relevance of the zebrafish as 
transplanted tumor cells faithfully recapitulate the human disease in vivo. The generation of 
zebrafish patient-derived xenografts (PDX) allows to assess the aggressiveness of the original 
patient tumor and helps to predict disease progression by investigating the capacity to invade 
and metastasize. 
Taken together, genetic and physiological similarities as well as supporting data generated by 
various studies involving transgenic zebrafish cancer models and zebrafish PDX models 
highlight the clinical relevance of the zebrafish as a powerful model to study cancer initiation 
and disease progression in order to develop novel anti-cancer therapies. 
 
 
 
 
 
 
 
 
 
 
Figure 8: Clinical relevance of zebrafish for human drug discovery 
Recent studies support the clinical relevance of the zebrafish model for human drug discovery by elucidating the 
degree of genetic similarity as well as conservation of target-proteins and drug metabolism pathways. 
Additionally, zebrafish physiology is well conserved as indicated by the example of cardiac electrophysiology 
which shows higher similarity to humans than rodents. According to that, several compounds discovered in 
zebrafish screens exhibit similar effects in rodent models and humans. Reprinted with permission from Springer 
Nature, from MacRae and Peterson, 2015. 
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2 DOCTORAL THESIS 
2.1 THESIS OBJECTIVES 
Cancer cells are characterized by an elevated and highly plastic redox environment. In order 
to compensate for intrinsic oxidative stress, cancer cells upregulate protective enzymes, such 
as MTH1, to eliminate erroneous bases and thereby promote both survival and growth under 
oxidizing conditions. Recently, we have developed potent in-house inhibitors that efficiently 
target MTH1 and induce cancer-specific cell death in vitro and in vivo
49,64
. 
As the reasons for cancer cells’ sensitivity to our in-house MTH1 inhibitors need to be further 
characterized, in Paper I, we aimed to determine factors that render cancer cells sensitive to 
the inhibitors. 
Based on the obtained results and in combination with the fact that the brain, due to its high 
energy consumption and metabolic rate, is more susceptible to oxidative stress than any other 
organ, in Paper II, we aimed to validate MTH1 as a target in GBM, specifically. 
GBM represents the most aggressive form of brain cancer and as today’s standard treatment 
fails to sufficiently eradicate the tumor, the prognosis remains dismal. Therefore, there is an 
urgent need to screen, identify and optimize novel anti-cancer drugs that could be used as 
future GBM treatments. In Paper III, we aimed to address this need by developing an 
orthotopic animal model for GBM that can be applied in automated drug discovery screens in 
order to facilitate the identification and optimization of novel promising anti-cancer drugs by 
simultaneously investigating drug toxicity and anti-tumor efficacy. 
The specific objectives of constituent thesis papers are recapitulated as follows and further 
addressed by answering the research questions, respectively: 
Paper I 
To describe factors that render cancer cells sensitive to MTH1 inhibitors 
 Identify factors that determine sensitivity to MTH1 inhibitors 
 Does the redox environment influence sensitivity? 
 
 Introduce zebrafish as a tool to study MTH1 biology 
 Do human MTH1 and zfMTH1 share high similarity? 
 Can the biology of oxidized nucleotides be studies in zebrafish?  
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 Investigate the link between hypoxia, VHL and MTH1 in vitro and in vivo  
 Is the hypoxia signaling axis involved in sensitizing to MTH1 inhibition?  
 Which role does VHL play in this szenario? 
 Do zebrafish experience increased oxidative stress upon activation of the 
hypoxia signaling axis? 
Paper II 
To validate MTH1 as a target in GBM and GBM stem cells  
 Study effects of MTH1 inhibitors on GBM and GBM stem cells in vitro 
 Do MTH1 inhibitors efficiently target GBM?  
 How potent are MTH1 inhibitors compared to GBM standard therapy? 
 Which phenotypes do GBM cells lacking MTH1 display?  
 Do MTH1 inhibitors target GBM stem cells? 
 
 Apply GBM zebrafish model to investigate effect of MTH1 inhibitors in vivo 
 Do MTH1 inhibitors target GBM in vivo?  
Paper III 
To develop an orthotopic in vivo model for GBM to facilitate screening, identification 
and optimization of novel anti-cancer drugs  
 Follow migration of GBM upon transplantation into zebrafish embryos 
 Where do GBM migrate to upon transplantation into the blastoderm of 
zebrafish embryos? Is the migration phenomenon specific for GBM? 
 
 Characterize brain tumors in vivo 
 Do transplanted GBM recapitulate clinical characteristics of the human 
disease? 
 Do transplanted GBM interact with host cells? 
 
 Apply GBM zebrafish model for a small drug screen 
 Is it feasible to subject transplanted, tumor-bearing embryos to small drug 
screens?  
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2.2 RESEARCH APPROACH 
In order to address the specific objectives of the constituent thesis papers, we followed a 
multidisciplinary approach including the zebrafish as a universal key tool in all publications. 
In a more general approach, we first began to identify factors that determine sensitivity of 
cancer cells to MTH1 inhibitors by combining biochemical and structural analysis with 
cellular assays and zebrafish in vivo studies. To get more specific, we next validated MTH1 
as a target in GBM and GBM cells by first analyzing datasets for a possible connection 
between MTH1 expression and brain cancer followed by numerous molecular biology and 
cellular assays combined with zebrafish in vivo studies. Finally, for the development of an 
orthotopic and fully automatable animal model for GBM, we again focused on the zebrafish 
as our in vivo model of choice as it is the only vertebrate animal model suitable for large-
scale drug discovery screens. Amongst other techniques, we combined xenotransplantation of 
GBM cultures with fluorescent imaging using confocal and light-sheet microscopy to 
characterize tumor growth in vivo.  
A detailed outline of the research approach is listed as follows: 
Paper I 
Identification of factors for cancer cells to be sensitive to MTH1 inhibitors  
1. Validation of redox environment as determinant of sensitivity to MTH1 inhibitors by 
altering redox levels with reducing and oxidizing agents to monitor survival and 
incorporation of oxidized nucleotides upon exposure to MTH1 inhibitors 
2. Comparative biochemical analysis of human MTH1 and zfMTH1 ± MTH1 inhibitors 
to display structural and functional similarity 
3. Microinjection of oxidized nucleotides into zebrafish eggs to investigate survival of 
zebrafish embryos upon exposure to MTH1 inhibitors 
4. Investigate link between hypoxia, VHL and MTH1 in vivo by exposing zebrafish with 
activated HIF1α signaling axis (transgenic VHL-/- zebrafish or chemical induction) to 
MTH1 inhibitors to assesss zebrafish survival 
5. Establish connection to redox environment by monitoring glutathione pool in 
transgenic zebrafish with activated HIF1α signaling axis ± MTH1 inhibitors 
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Paper II 
Validation of MTH1 as a target in GBM and GBM stem cells 
1. Dataset analysis to determine connection between MTH1 expression and GBM  
2. RNAi-mediated knockdown of MTH1 versus in-house MTH1 inhibitors to 
investigate effects on cell proliferation, cell cycle and survival  
3. Comparision of cell survival upon exposure to MTH1 inhibitors and GBM standard 
therapy  
4. Analysis of DNA damage marker expression to relate effects of MTH1 inhibitors on 
GBM cells to oxidized nucleotide sanitation  
5. Investigation of MTH1 inhibitor-induced effect on GBM stem cells (GSCs) by 
analysis of cell proliferation, cell cycle, survival and incorporation of oxidized 
nucleotides  
6. Exploration of clinical relevance by investigating the effect of MTH1 inhibitors on 
GBM in vivo using transplanted zebrafish embryos  
 
Paper III 
Development of an orthotopic and fully automatable in vivo model for GBM  
1. Identification of predominant migration site within zebrafish embryo by monitoring 
migration of transplanted GBM cells in vivo 
2. Assessment for GBM specificity of migration site by transplanting and monitoring 
migration of different cancer types  
3. Determination of clinical relevance of GBM zebrafish model by investigating clinical 
characteristics such as growth and invasion capacity of transplanted tumors as well as 
interactions with host cells such as the vascular and immune system by using 
transgenic zebrafish lines 
4. Validation of applicability of GBM zebrafish model in drug discovery screens by 
performing a luciferase-based test screen (see chapter “Key Methodology”)  
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2.3 KEY METHODOLOGY 
During the last decades, the zebrafish has become the flagship model organism to study 
vertebrate development
113
 integrative physiology
114
, toxicology
115
 and more recently, 
cancer
116–118
. The application of zebrafish as a preclinical model for numerous cancer types 
has contributed significantly to a better understanding of cancer biology while simultaneously 
emerging as a promising, clinically relevant “tool” for high-throughput drug discovery 
screens potentially creating the leap towards precision medicine, the future of cancer 
treatments. 
Thanks to its highly beneficial features including both biological and technical advantages 
(see chapter “The Zebrafish as a Model Organism”), the zebrafish is the only vertebrate 
animal suitable for high-throughput drug screens. This fact is strongly supported by a 
landmark screen performed in 2000, which highlights the general applicability of zebrafish in 
high-throughput drug screens by investigating toxicological effects of small molecules on 
organ development in whole zebrafish larvae using a 96-well format
158
. Until today, hundreds 
of such screens using zebrafish model organisms have been performed covering a diversity of 
research questions and compound library sizes
159
 while complementing developmental 
phenotypes with the use of behavioral, cardiac, metabolic, proliferative and regenerative 
read-outs. Generally, phenotype-based screens are known for a higher success rate compared 
to target-based screens as they may identify effective drugs with a beneficial outcome in the 
absence of a validated target. As described by Swinney and Anthony in 2011, more than half 
of all approved first in-class drugs between 1999 and 2008 were discovered in phenotype-
based screens
160
, thereby significantly improving the life of many patients. 
Here, we combine both biological and technical advantages of the zebrafish, most 
importantly its high clinical relevance indicated by the strong disease-capitulating quality of 
zebrafish xenograft models with the promising success rate of phenotype-based screens. In 
Paper III of this thesis, we present an orthotopic and fully automatable zebrafish model for 
GBM which opens up a new avenue for in vivo high-throughput drug screens offering great 
preclinical potential to 1) identify and optimize novel effective anti-GBM drugs, 2) accelerate 
repurposing of already existing drugs and 3) promote screening for tailor-made drugs, as a 
step towards personalized medicine. 
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2.3.1 Application of orthotopic GBM zebrafish model in drug screen 
The following chapter focusses on describing the key methodology of this thesis, the 
generation of an orthotopic zebrafish model for GBM and its application in a small drug 
screen. It comprises detailed information on 1) the cultivation and preparation of human cell 
cultures and their transplantation into blastula stage zebrafish embryos, 2) the exposure of 
tumor-bearing zebrafish embryos to compounds and 3) the measurement of bioluminescence 
to determine tumor size in vivo (Figure 9). Following a brief discussion about issues and 
complications that were overcome during the development of the underlying transplantation 
technique, the chapter closes with highlighting the advantages of our novel orthotopic 
zebrafish model for GBM, while balancing against limitations for its application. 
 
 
Figure 9: Schematic timeline of drug screen process 
At 2.5 - 3 hpf, GBM cells stably expressing luciferase are harvested and transplanted into wildtype TL zebrafish 
embryos. Transplanted GBM cells migrate to the CNS to form a solid tumor. At 24 hpf, tumor-bearing zebrafish 
embryos are sorted, dechorionized and divided into groups to begin compound exposure. At 96 hpf, tumor size 
of transplanted and exposed zebrafish is determined by measuring bioluminescence individually in a luciferase 
end-point assay and quantitatively analyzed. Luc, luciferase; GBM, glioblastoma; hpf, hours post fertilization; 
zf, zebrafish. 
Cell preparation and transplantation 
For the drug screen presented in Paper III, we have used two GBM cultures, patient-derived 
GBM culture #18
161
 and U343-MGa
162
. Both GBM cultures have been propagated in 
Minimum Essential Medium (Gibco) containing 2 mM glutamine (Gibco) at 37°C in a 
humidified atmosphere with 95 % humidity and 5 % CO2. For further details on generation 
and characterization of GBM cultures, please view respective references. 
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In all experiments, GBM tumor size was determined by measuring bioluminescence using an 
in vivo luciferase reporter assay. For this, GBM culture #18 and U343-MGa were stably 
transfected with luciferase using standard lentivirus protocols. 
After successful transfection and recovery, GBM cultures were transferred to complete 
neurobasal stem cell medium at least 5 days prior to transplantation to enhance tumor 
engraftment. GBM cultures were grown until subconfluency and harvested one hour before 
transplantation. For the generation of a single cell suspension, cells were passed through a 
pre-washed 20 µm cell strainer. Next, cells were washed, spun down and after removal of the 
supernatant, cells were resuspended in medium containing 2 % polyvinylpyrrolidone (PVP) 
to prevent clogging of the microinjection capillary (World Precision Instruments). Harvested 
cells were kept on ice until transplantation.  
Immediately before transplantation, cells were spun down again and the supernatant was 
almost entirely removed, generating a highly concentrated cell suspension, which was loaded 
manually into a microinjection capillary. 
Zebrafish embryos were collected at 3 hpf and immobilized in 2 % agarose injection plates. 
Approximately 100 cells were transplanted into the blastoderm of the zebrafish embryos. 
Following transplantation, zebrafish embryos were transferred to E3 fish medium into a 
10 cm petri dish and incubated at 33°C for 24 hours before screening and drug exposure.  
Compound exposure of tumor-bearing zebrafish embryos 
The next day, transplanted zebrafish embryos were screened for viability and brain tumor 
establishment. To ensure homogenous drug exposure, zebrafish embryos were dechorionized 
using 2 mg/mL Pronase® (from Streptomyces griseus) and distributed to 6-well plates (20 - 
25 embryos/well) in a total volume of 3 mL E3 fish medium containing 25 mM HEPES (4-
(2-hydroxyethyl)-1-piperazine ethanesulfonic acid) as buffer. Compounds of interest 
dissolved in DMSO (dimethyl sulfoxide) to 10 mM were added directly to the medium to 
reach a desired end concentration. DMSO was used as vehicle control. During drug exposure, 
zebrafish embryos were incubated at 33°C for 72 hours (unless stated differently). 
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End-point assay: Measurement of bioluminescence to determine tumor size in vivo 
As described before, all transplanted GBM cultures were stably expressing a firefly luciferase 
enzyme, which converts substrate D-luciferin to its corresponding product oxyluciferin in the 
presence of cofactors ATP, magnesium and oxygen, while simultaneously emitting light as a 
by-product (Figure 10). The amount of light produced is proportional to the amount of 
luciferase enzyme. In the context of our small drug screen, the amount of light produced 
reflects the number of GBM tumor cells, and hence tumor size in vivo. 
Tumor size of transplanted and exposed zebrafish embryos was determined by measuring 
bioluminescence individually. For this, single zebrafish embryos were transferred to opaque 
96-well plates (Perkin Elmer) and incubated for 30 min in lysis buffer (10 % glycerol, 1 % 
Triton-X 100, 1 mM DTT (1,4-dithiothreitol), pH 7.8). An equal amount of substrate solution 
(1 mM DTT, 1 mM ATP, 0.3 mg/ml D-luciferin, pH 7.8) was added for 5 min before 
measurement of bioluminescence (Hidex Sense).  
 
 
 
 
 
 
 
 
 
 
 
Figure 10: Simplified bioluminescence reaction mechanisms  
Luciferase converts substrate D-luciferin to its corresponding product oxyluciferin in the presence of cofactors 
ATP, magnesium and oxygen, while bioluminescence is emitting as a by-product. Note: cofactor requirements 
are dependent on the luciferase used (here: firefly luciferase). ATP, adenosine triphosphate; Mg, magnesium; O2, 
oxygen; PPi, diphosphate; AMP, adenosine monophosphate, CO2, carbon dioxide. 
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Statistical Analysis 
All experiments were performed at minimum in triplicates. The results are presented in mean 
± SD. Statistical significance was determined using the One sample t-test (online GraphPad 
Software, 2018). The following P-values were considered significant: *P < 0.05, **P < 0.01, 
***P < 0.001, ****P < 0.0001. 
2.3.2 Issues and complications  
In the course of establishing the protocol for our novel orthotopic zebrafish model, we came 
across several issues that needed further optimization, or complications that have to be 
considered when performing the transplantation procedure, prospectively. 
First of all, aside the fact that around 70 % of zebrafish embryos transplanted with GBM 
cultures developed congregated brain tumors at 24 hpf, we occasionally observed some of the 
transplanted candidates with severe developmental defects or malformations including the 
development of a second body axis, or reduction of the tail. Due to the fact that zebrafish 
embryos are highly susceptible to disruptions in their early development, we concluded that 
these phenomena have to be time-dependent issues, as the incidence of developmental defects 
could be reduced when performing transplantations from 2.5 - 3 hpf on. 
In addition to developmental defects, at times we observed edema formation in transplanted 
zebrafish embryos around 48 hpf. Following a more detailed analysis, we found that 
zebrafish embryos harboring CNS tumors in close proximity to the heart region were more 
likely to develop edemas. Intriguingly, peritumoral edema formation is also commonly found 
in GBM patients as suggested by recent clinical data
163–165
. It is believed that glioma-related 
edema (GRE) formation promotes tumor cell invasion and significantly influences the 
prognosis
164
, thus serving as a diagnostic marker for clinical outcome of GBM patients. 
Another complication that we were facing while developing the protocol for our novel 
orthotopic zebrafish model was the large variation of tumor sizes in vivo. The reason for this 
variation is a technical issue: due to their large size as well as their morphological features, 
GBM cells tend to block the microinjection capillaries, which can be further aggravated by 
residual dye and dust particles. In case of a blocked microinjection capillary, several options 
exist on how to eliminate the blockage such as 1) increasing the pressure of the micro-
injector, 2) increasing the diameter of the microinjection capillary to remove the particle from 
the capillary, or 3) preparing a new microinjection capillary. In any case, the number of 
transplanted cells will ultimately change. Following intense optimization of the cell 
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preparation protocol prior to transplantation by adding multiple washing steps or 
supplementing medium with PVP to increase viscosity, we could reduce the variation of 
tumor sizes in vivo. However, as the technical issue still persists in some cases, extreme 
tumor sizes revealed by luciferase measurement should be excluded from the analysis as 
outliers. 
Currently, we determine individual tumor sizes by measuring bioluminescence in an endpoint 
assay. As mentioned before, large variations in tumor sizes minimize any biologically 
significant effect on tumor reduction. One way to further optimize the read-out would be to 
follow individual tumor sizes in real-time. Recently, a group has engineered a luciferin 
analog “AkaBLI”, which produces light emissions in vivo that are 100 to 1000 brighter 
compared to conventional systems and therefore allow for noninvasive visualization of single 
cells in deep tissue
166. The generation of GBM cultures stably expressing “AkaBLI” would 
significantly improve our zebrafish model as we could measure bioluminescence and hence, 
tumor volume in real-time at any desired time-point without lysing the zebrafish. 
2.3.3 Advantages and limitations 
Xenograft models remain the gold standard for understanding GBM tumor biology in vivo. 
Although recapitulating the human disease sufficiently well, orthotopic rodent models for 
GBM are both technically and ethically challenging as well as time-consuming, and therefore 
not suitable for drug screens. The zebrafish offers a clinically relevant alternative to rodent 
models; however, currently existing orthotopic zebrafish models for GBM are generated by 
laborious intracranial transplantation of single zebrafish embryos, which limits their use in 
drug screens. Our newly developed zebrafish model for GBM closes the gap by offering a 
clinically relevant yet fully automatable orthotopic model for GBM that is suitable for high-
throughput drug screens. Some of its numerous advantages are listed as follows: 
 Tumor formation in the CNS within 24 hours 
Patient-derived tumor material and established GBM cultures specifically migrate to 
the CNS upon transplantation in the blastoderm of zebrafish embryos at 2.5 - 3 hpf to 
form a congregated tumor within 24 hours. 
 Fast and fully automatable transplantation procedure 
Tumor establishment in the CNS of zebrafish embryos is independent of injection site 
within the blastoderm; thus, transplantation of GBM cultures could be performed by 
existing robotic injection systems. 
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 Implementation in fully automatable drug discovery pipeline 
Zebrafish embryos can be raised, treated and screened in 96-well plate format. 
Depending on the instruments included in the drug screen pipeline, it is possible to 
simultaneously monitor tumor size as well as vital parameters to evaluate the overall 
being of exposed zebrafish embryos. 
 High clinical relevance 
Within few days, transplanted GBM cells faithfully recapitulate the human disease in 
the zebrafish, which is characterized by the formation of brain microtubules and 
invasion of the surrounding brain tissue, vessel formation and interactions with the 
innate immune system such as macrophages. In addition to that, the formation of the 
BBB at 3 dpf limits potential drug screen hits to drugs that display chemical 
properties to actually pass the BBB to induce an anti-tumor effect. 
 Time-efficient pipeline 
Robust and predictive drug screen within 5 days 
 No ethical restrictions 
As no requirement of an ethical permit is needed below 5 days, the model complies 
with the 3R guidelines (replace, reduce, refine). 
 
Despite numerous highly relevant advantages, our orthotopic zebrafish model for GBM 
comprises few limitations. As mentioned before, the adaptive immune system is not 
functional until 4 - 6 weeks post fertilization
133,134
 and limits studies focusing on the interplay 
between transplanted cancer cells, the immune system and how treatment efficacy is affected 
as it may not fully reproduce the behavior of cancer in a fully immunocompetent host. 
Additionally, cancer cells might display altered phenotypes upon transplantation into the 
embryonic environment of a developing zebrafish embryo
124
 which has to be considered 
when interpreting study results. Another limitation is presented by the duration of the 
experimental pipeline, which is as short as 5 days. Prolonging the experimental pipeline to 
follow treatment effects for an extended period of time is generally possible but requires 
further optimization regarding the tumor burden of transplanted zebrafish embryos. 
Additionally, zebrafish studies that exceed 5 days require ethical permits.  
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2.4 SUMMARY OF RESEARCH PAPERS 
2.4.1 Paper I: Hypoxic Signaling and the Cellular Redox Tumor Environment 
Determine Sensitivity to MTH1 Inhibition 
As explicitly addressed in the introduction, cancer cells are characterized by an elevated and 
highly plastic redox environment. To compensate for intrinsic oxidative stress, cancer cells 
upregulate sanitizing enzymes, such as MTH1, which eliminate oxidized nucleotides and 
thereby promote both survival and growth under oxidizing conditions. After the development 
of potent in-house inhibitors that efficiently target MTH1 and induce cancer-specific cell 
death
49
, in Paper I, we aimed to determine factors that render cancer cells sensitive to MTH1 
inhibitors, predominantly focusing on compound TH588.  
Recent publications postulated that the loss of functional MHT1 correlates with an increased 
incorporation of 8-oxo-dGTP into DNA
49,62
. Based on the observation that elevated levels of 
total glutathione in cancer cells also correlate with increased sensitivity to MTH1 inhibition, 
we first investigated whether the redox environment itself determines sensitivity to MTH1 
inhibitor TH588. Indeed, we could show that increasing oxidative stress in non-malignant 
cells by blocking their glutathione de novo synthesis induces their sensitization to MTH1 
inhibition by TH588. In contrast to that, decreasing the oxidative pressure in cancer cells 
using general anti-oxidants such as N-acetyl-L-cysteine (NAC) protects against MTH1 
inhibition by TH588 (Paper I, Figure 1a, 1b).  
Next, we identified the zebrafish model as a useful tool to study MTH1 biology as human 
MTH1 and zfMTH1 share high similarity on amino acid level (70 % identity). Furthermore, 
we cloned, expressed and purified zfMTH1 and found that the human MTH1 inhibitor 
TH588 shows similar affinity to the active site of zfMTH1 as to human MTH1, a prerequisite 
to further study TH588 in vivo (Paper I, Figure 2). 
In order to determine whether functional MTH1 is required to detoxify oxidized nucleotides 
in vivo, we microinjected 8-oxo-dGTP and 2-OH-dATP into zebrafish eggs. As the deoxy 
form of oxidized nucleotides can readily be incorporated into DNA, we discovered that the 
delivery of both 8-oxo-dGTP and 2-OH-dATP to zebrafish eggs is highly toxic in the absence 
of functional MTH1 (Paper I, Figure 3).  
Based on the interplay between redox signaling networks and hypoxia sensing mechanisms, 
we next investigated whether an activated hypoxia signaling axis also sensitizes to MTH1 
inhibition using TH588. For that, we mimicked activated hypoxia signaling either genetically 
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by developing homozygous VHL knockout zebrafish, or chemically by inactivating prolyl 
hydroxylases (PHDs) using DMOG (dimethyloxaloylglycine). In both cases, zebrafish 
embryos were sensitized to MTH1 inhibitor TH588 by showing significantly reduced 
viability (Paper I, Figure 4, Figure 5a, and b).  
Lastly, using a transgenic zebrafish line to monitor the cellular redox state in vivo, we 
detected an increase in oxidative pressure upon activation of hypoxic signaling. As the 
pretreatment with anti-oxidant NAC protects embryos with activated hypoxia signaling 
against MTH1 inhibition, we concluded that an aberrant redox environment causes 
sensitization (Paper I, Figure 5c, and d).  
Summarizing the results obtained in Paper I, we conclude that MTH1 inhibition may offer a 
general approach to treat cancers that are characterized by elevated oxidative stress levels and 
a deregulated hypoxia signaling axis by inducing cancer-specific cell death via incorporation 
of erroneous bases into DNA (Figure 11).  
 
Figure 11: Overview on how elevated redox pressure sensitizes cancer cells to MTH1 inhibition 
Due to the activation of oncogenes, hypoxic conditions as well as deregulated hypoxia signaling pathways, 
cancer cells suffer from elevated redox pressure. As the nucleotide pool is especially prone to oxidative damage, 
it requires the enzymatic activity of MTH1 for sanitation. If MTH1 is inhibited, oxidized nucleotides are 
incorporated into DNA leading to DNA damage and eventually, cancer cell death. MTH1, MutT homolog 1; 
DNA, deoxyribonucleic acid.  
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2.4.2 Paper II: Glioblastoma and glioblastoma stem cells are dependent on 
functional MTH1 
Based on the results obtained in Paper I, we next planned to validate MTH1 as an anti-
cancer target in a specific cancer type that is characterized by elevated oxidative pressure and 
increased anti-oxidant defense mechanisms. Knowing that the brain, due to its high energy 
consumption and metabolic rate, is more susceptible to oxidative stress than any other organs, 
in Paper II, we aimed to investigate the effect of our in-house MTH1 inhibitors in brain 
cancer.  
First, we started by analyzing available cancer datasets for a potential connection between 
MTH1 and brain cancer, and found consistent evidence that MTH1 mRNA expression levels 
are upregulated in GBM compared to non-tumor brain tissue. Following this significant 
correlation, we investigated the effect of our in-house MTH1 inhibitor TH588 and its 
pharmacologically and pharmacokinetically improved version TH1579 on the survival of 
different GBM cell lines. Indeed, we found that both inhibitors decrease viability of all GBM 
cell lines following a 3- or 5-day treatment (Paper II, Figure 1b). 
Intrigued by these initial findings, we continued to assess the requirement of functional 
MTH1 for GBM cell viability in a panel of patient-derived GBM cultures divided into type A 
and B depending on their tumorigenic activity and amount of GSCs. We found that both 
inhibitors TH588 and TH1579 significantly decrease viability of all GBM cultures 
independent of their intrinsic aggressiveness. To further confirm the requirement of 
functional MTH1, we chose a representative GBM culture of type A (GBM #18) and type B 
(GBM #7), and depleted MTH1 either by siRNA-mediated knockdown using different 
sequences or by small molecule inhibition using TH588 and TH1579. In both cases, we 
observed an efficient reduction of GBM survival as depicted by clonogenic survival assay as 
well as cell cycle analysis (Paper II, Figure 2).  
Comparing our in-house MTH1 inhibitors TH588 and TH1579 to today’s standard treatment 
and other clinical candidates targeting GBM, we found that TH1579 is more potent in 
eradicating GBM #18 cells (Paper II, Figure 3).  
Next, we analyzed DNA damage markers to relate the effects of our MTH1 inhibitors on 
GBM cells to oxidized nucleotide sanitation. Indeed, we found prolonged tail moments by 
comet assay and increased numbers of γH2AX foci as revealed by immunofluorescent (IF) 
analysis, indicating that the effect of MTH1 loss on GBM is likely mediated through 
incorporation of oxidized nucleotides and subsequent DNA damage (Paper II, Figure 4).  
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One major factor that determines GBM aggressiveness and treatment resistance is the highly 
heterogeneous nature of the GBM tumor bulk, which comprises a large number of GSCs 
characterized by cell surface marker CD133. Therefore, we aimed to explore if our MTH1 
inhibitors target both CD133
+
 and CD133
- 
GBM cells. Indeed, we found that inhibition of 
MTH1 with TH588 and TH1579 decreases both populations by impairing CD133
+
 and 
CD133
-
 GBM cell viability. Moreover, life cell imaging of GSCs characterized by 
transcription factor SOX2 (SRY (sex determining region Y)-box 2) revealed a significantly 
prolonged mitosis upon exposure to TH588 and TH1579, proving further evidence that 
MTH1 inhibition targets GSCs (Paper II, Figure 5).  
 
 
Figure 12: Dependency of GBM and GBM stem cells on functional MTH1 
GBM cultures display elevated MTH1 expression levels, which correlate with GBM aggressiveness 
characterized by proliferation rate and amount of GBM stem cells, amongst others. Following depletion of 
MTH1 either by siRNA-mediated knockdown or small molecule inhibition using in-house synthesized MTH1 
inhibitors TH588 and TH1579, viability of GBM cultures independent of intrinsic aggressiveness is significantly 
reduced in vitro and in vivo, using an orthotopic zebrafish model for GBM (shown in this figure: zebrafish 
embryos orthotopically transplanted with GBM and incubated in a 96-well plate). The effect of MTH1 loss on 
viability is most likely mediated by incorporation of oxidized nucleotides and subsequent DNA damage, 
rendering MTH1 as a promising target for GBM therapy. GBM, glioblastoma; MTH1, MutT homolog 1; DNA, 
deoxyribonucleic acid; 8-oxo-dGTP, 8-oxo-7,8-dihydroxy-2’-deoxyguanosine-5’-triphosphate.  
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Finally, to investigate the effect of our MTH1 inhibitors on GBM in vivo, we transplanted 
luciferase positive GBM cells enriched for CD133 into zebrafish embryos and exposed them 
to TH1579. Bioluminescence measurement of tumor size in vivo after 5 days of treatment 
revealed a significant reduction in tumor volume compared to the control. Additionally, in 
vivo real-time imaging of exposed tumors via light-sheet microscopy revealed numerous 
GBM cells undergoing cell death confirming the overall reduction in tumor volume by 25 % 
(Paper II, Figure 6). 
To conclude, with these in vitro and in vivo results, we provide supporting data that the 
inhibition of MTH1 using our in-house inhibitors TH588 and its pharmacologically and 
pharmacokinetically improved version TH1579 might present an efficient strategy to target 
heterogeneous GBM tumors (Figure 12). 
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2.4.3 Paper III: An orthotopic glioblastoma animal model suitable for high-
throughput screenings 
GBM is the most aggressive form of brain cancer and as today’s standard therapy fails to 
sufficiently eradicate the tumor, there is an urgent need for novel GBM treatments. However, 
the development of novel GBM treatments is hampered by the lack of orthotopic animal 
models that can be implemented in high-throughput drug discovery screens. In Paper III, we 
aimed to address this issue by developing an orthotopic animal model for GBM that can be 
applied in automated drug discovery screens in order to facilitate the identification and 
optimization of novel promising anti-cancer drugs against GBM by simultaneously 
investigating drug toxicity and anti-tumor efficacy.  
Based on fate-map analysis and previous data suggesting that early zebrafish embryos could 
provide lineage-specific trophic support to human cells, we hypothesized that human GBM 
cells transplanted into the zebrafish blastoderm might migrate into CNS structures of the 
developing zebrafish embryo. Indeed, 24 hours later around 70 % of transplanted zebrafish 
embryos develop an intracranial tumor (Paper III, Figure 1). By transplanting patient-derived 
GBM cultures, more established GBM cell lines as well as colorectal cell lines cells to 
compare the migration sites, respectively, we elucidated that the migration behavior into the 
CNS regions is GBM specific, but independent from the transplantation site within the 
blastoderm of the zebrafish embryo (Paper III, Figure 2).  
After confirming the robustness of our model, we explicitly analyzed its clinical relevance. 
Real-time light-sheet microscopy revealed that transplanted GBM cells actively proliferate in 
vivo leading to an increased tumor volume within 24 hpf (Paper III, Figure 3a - d). In addition 
to that, transplanted GBM cells invade into the healthy surrounding brain tissue by 
developing extended tumor microtubules, which steadily grow (until the humane endpoint of 
the experiment at 6 dpf is reached, Paper III, Figure 3e - f). Moreover, transplanting GBM 
cells into transgenic zebrafish embryos (fli:eGFP) that harbor a fluorescent blood vessel 
system revealed ongoing tumor vascularization (Paper III, Figure 4a, and b). On top of that, 
upon the transplantation of GBM cells into transgenic zebrafish embryos expressing 
fluorescent proteins in macrophages (mpeg1:mCherry), we observed tight interactions 
between the innate immune system and the transplant (Paper III, Figure 4c).  
In order to provide evidence that our orthotopic model for GBM is applicable for drug 
discovery screens, we performed a small drug screen testing the anti-tumor efficacy of 
several tyrosine kinase inhibitors (TKIs) including Erlotinib, R-Crizotinib, Gefitinib and 
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Afatinib on GBM in vivo. First, we engineered both the well-established GBM cell line 
U343-MGa as well as patient-derived GBM culture #18 to stably express luciferase. Next, we 
transplanted zebrafish embryos and exposed them to the TKIs. Following an exposure of 
3 days, tumor volume of single embryos in vivo was assessed by bioluminescence 
measurement and revealed that Erlotinib reduces tumor burden of U343-MGa transplanted 
zebrafish embryos most significantly compared to the control. Albeit displaying similarly 
significant responses to the treatment, patient-derived GBM culture #18 are generally less 
sensitive to the TKIs (Paper III, Figure 4g).  
Taken together, the thorough characterization of the orthotopically transplanted GBM tumors 
in vivo highlights numerous features including active proliferation, tumor growth, and 
formation of tumor microtubules, induction of angiogenesis as well as interaction with the 
innate immune system of the host, which are highly reminiscent of human brain tumors. 
Hence, our model faithfully recapitulates the human disease in vivo, while enabling the 
transplantation of thousand embryos per hour, thereby being applicable for fully automatable 
drug discovery screens (Figure 13). 
 
 
 
 
 
 
 
 
 
Figure 13: Application of orthotopic zebrafish model for GBM in automated large-scale drug screen 
At 2.5 - 3 hpf, hundreds of zebrafish embryos can be lined up in agarose injection plates to be transplanted with 
GBM material by robotic injection systems (A). At 24 hpf, transplanted embryos are screened for tumor size by 
automated imaging systems (B) and automatically distributed into 96-well plates preloaded with candidate 
compounds (C). After 3 days incubation time, individual embryos are automatically sampled, imaged, and 
analyzed with commercially available instruments (D). GBM, glioblastoma; hpf, hours post fertilization. 
Reprinted with permission from Oxford University Press, from Pudelko et al., 2018.  
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2.5 DISCUSSION  
As currently available treatment options for neurological cancers are limited and lethal tumor 
recurrence is inevitable, GBM remains one of the most intractable forms of cancer, creating 
an urgent need for the development of innovative therapeutic approaches. Advances in 
sequencing technology and the resulting discovery of GBM-associated oncogenic driver 
mutations and altered protein expressions opened the promising avenue of targeted therapy
72–
74
. However, despite the discovery of various targets
167
, the development of potent drugs 
leading to complete destruction of the tumor remains challenged by 1) the complex biology 
of GBM including its extensive tumor heterogeneity, cancer cell plasticity and the presence 
of cancer stem cells
16,75,76
, 2) physical barriers that hamper drug delivery such as the BBB 
and blood-tumor barrier (BTB) and 3) the lack of predictive animal models suitable for high-
throughput drug discovery screens.  
In the underlying work of this PhD thesis, we first addressed the issue of GBM tumor 
heterogeneity as a major challenge for the development of efficient therapies by focusing on a 
more general/broad cancer-specific target: the elevated and highly plastic redox environment 
of cancer cells. To compensate the detrimental effect of increased ROS production, cancer 
cells and GBM in particular depend on effective anti-oxidant defense systems and non-
oncogenic addiction enzymes such as MTH1, an enzyme that detoxifies oxidized bases to 
prevent DNA damage and subsequent cell death. 
At the time this thesis work commenced, we have developed potent in-house inhibitors that 
efficiently target MTH1 and induce cancer-specific cell death in vitro and in vivo 
49,64
. As the 
reasons for cancer cells’ sensitivity to our in-house MTH1 inhibitors required further 
characterization, in Paper I, we first aimed to determine factors that render cancer cells 
sensitive to our MTH1 inhibitors. Following the hypothesis that the brain, due to its high 
energy consumption and metabolic rate, is more susceptible to oxidative stress than any other 
organ, in Paper II, we aimed to validate MTH1 as a target in GBM, specifically.  
In the last part, we addressed the lack of predictive animal models for GBM that are suitable 
for high-throughput drug discovery screens. Following the introduction of the zebrafish as a 
clinically relevant model for human malignancies including cancer, in Paper III, we have 
developed an orthotopic and fully automatable animal model for GBM with the potential to 
1) identify and optimize novel effective anti-GBM drugs, 2) accelerate repurposing of already 
existing drugs and 3) promote screening for tailor-made drugs, as a step towards personalized 
medicine. 
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2.5.1 Paper I 
Activated hypoxia signaling frequently displayed in solid cancers and associated with poor 
clinical prognosis is a direct consequence of overexpressed HIF1α either induced by hypoxic 
tumor regions or by oncogenic signaling and growth factor stimulation
20,168,169
. Indirect 
activation of the hypoxia signaling axis can be induced by the absence of tumor suppressor 
protein VHL as a consequence of somatic mutations
170
. Increased HIF1 activity alters cellular 
metabolism leading to persistently upregulated ROS levels. Cancer cells ensure survival and 
growth under oxidizing conditions by increasing their anti-oxidant ability, which 
consequently shifts the overall redox balancing point upwards (Figure 4a) and fuels a vicious 
cycle of further adaption, continuous proliferation and acquisition of DNA damage and 
genomic instability. While simply increasing ROS levels to induce cancer cell death remains 
insufficient, disabling ROS defense systems by targeting anti-oxidant or other non-oncogenic 
addiction enzymes such as MTH1 represents an area of therapeutic opportunities
46,49
. 
Following the development of potent in-house inhibitors that efficiently target MTH1 and 
induce cancer-specific cell death in vitro and in vivo
49
, we aimed to understand the underlying 
mechanism of cancer cells’ sensitivity to the MTH1inhibitors. 
Despite the highly plastic intracellular redox environment, we were able to show that the 
exposure of healthy cells to oxidants or the depletion of the cellular glutathione pool 
increased their sensitivity to MTH1 inhibition. This was in line with previous findings 
indicating that the exposure to hydrogen peroxide sensitized both fibroblasts and cancer cells 
to siRNA-mediated knockdown of MTH1
171
. In addition, we could show that decreasing the 
oxidative pressure in cancer cells using anti-oxidants such as NAC protected against MTH1 
inhibition. Based on our data we concluded that the redox environment is a key factor in 
determining sensitivity to MTH1 inhibition.  
Due to the close connection between the oncogenic redox environment and deregulated 
hypoxia signaling described earlier, we employed transgenic zebrafish embryos to study if 
MTH1 inhibition is connected to VHL activity. Indeed, we were able to show that the loss of 
endogenous VHL or the chemical activation of HIF1α signaling sensitized to MTH1 
inhibition in vivo. According to the hypothesis that hypoxia leads to a more oxidized cellular 
and mitochondrial environment induced by ROS formation at complex III of the 
mitochondrial electron transport chain (ETC), using a transgenic zebrafish embryos 
genetically encoding a glutathione sensor, we could show that chemical activation of HIF1α 
signaling indeed increased oxidative pressure. As zebrafish embryos can be protected against 
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MTH1 induced death by exposure to anti-oxidants, we concluded that an elevated redox 
environment in combination with deregulated hypoxia signaling might be the underlying 
cause for sensitization to MTH1 inhibition. 
Targeting MTH1 as a secondary ROS defense system 
Cellular ROS defense systems contain endogenous enzymatic anti-oxidants and non-
oncogenic addiction enzymes such as MTH1. MTH1 plays an important role in nucleotide 
metabolism by hydrolyzing 8-oxo-dGTP and 2-OH-dATP to their respective 
monophosphates
61
, thereby preventing incorporation of these erroneous nucleotides into 
DNA and potentially lethal consequences
49
 (Figure 5). While being non-essential in non-
transformed cells, as shown by MTH1 knockdown mice that live long and grow old
49,172
, 
cancer cell depend on MTH1 as a nucleotide sanitizing enzyme. Attributed to this function, 
MTH1 is part of a secondary ROS defense system and represents a favorable and druggable 
target in cancer cells by performing oxidative damage control
173
. In contrast to MTH1, other 
endogenous anti-oxidant defense systems are involved in the primary regulation of redox 
homeostasis and potentially provide additional targets, such as the anti-oxidant master 
regulator Nrf-2. Playing a crucial role in tumor progression and correlating with poor clinical 
outcome, Nrf-2 regulates anti-oxidant response genes involved in glutathione (GSH) 
synthesis, metabolism and other cyto-protective mechanisms
174
. Moreover, the plant derived 
compound Brusatol was able to decrease Nrf-2 protein levels, thereby improving sensitivity 
to chemotherapeutics such as Cisplatin and Gemcitabine
175
. Other groups have developed 
small molecule inhibitors against Nrf-2
176
 or used retinoic and ascorbic acid to suppress Nrf-2 
activity
177
. However, it remains debatable if the therapeutic window between healthy and 
malignant cells is sufficient when systemically targeting Nrf-2, or if this could lead to adverse 
side-effects in healthy cells to the extent of promoting malignant transformation. The same 
will likely be true for systemic inhibition of cellular anti-oxidants such as GSH, thioredoxin 
(TXN) or superoxide dismutase (SOD). Although several studies support the theory that 
direct inhibition of these cellular anti-oxidants sensitized cancer cells to chemo- and 
radiotherapy in vitro
178–181
, there is a realistic chance that such treatment, i.e. using natural 
compounds, can evoke adverse effects in patients, dependent on dosing and timing
182
. Thus, 
targeting more cancer-specific secondary ROS defense systems, i.e. by inhibiting MTH1, 
seems to be a more favorable approach than disrupting primary multifunctional ROS defense 
systems in order to eliminate heterogeneous cancer cells while sparing healthy cells. 
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Clinical application  
With the results presented in Paper I, we have provided evidence that both, activated 
hypoxia signaling as well as the oncogenic redox environment, determine sensitivity to 
MTH1 inhibition, which originates from an increased reliance on damaged nucleotide 
sanitation. Indeed, overexpression of MTH1, highly associated with poor prognosis, can be 
found in several cancer types including GBM, liver, gastric and lung cancer
183–186
. Supported 
by preclinical studies, MTH1 inhibition could be used as monotherapy
187–189
 or in 
combination with conventional chemotherapy as well as ROS inducing agents for enhanced 
sensitivity
187,190
 to target different cancer indications, even those displaying tumor 
heterogeneity and poor prognosis. Given the fact that radiotherapy induces endogenous ROS 
production and promotes nucleotide damage-induced cell death, it is plausible to speculate 
that MTH1 inhibitors could be used as radio-sensitizers or in combination with 
radiotherapy
190
. 
Aside from cancer, other major health issues including neurodegenerative diseases such as 
Alzheimer
191
 and Parkinson
192
 as well as rheumatoid arthritis
193
 are characterized by a 
specific, more oxidized redox environment, offering further clinical indications for MTH1 
inhibition. 
Supported by promising preclinical in vitro and in vivo data, clinical candidate Karonudib 
(TH1579) is currently evaluated for the treatment of cancer in a clinical phase I study 
(ClinicalTrials.gov Identifier: NCT03036228). 
Challenges 
Despite the development of several potent small molecule inhibitors against MTH1 as well as 
the support of preclinical in vitro and in vivo studies
49,187–189
, the emerging role of MTH1 as a 
promising anti-cancer drug target has been challenged. Studies from independent groups 
report that some of the new and potent inhibitors for MTH1, albeit inhibiting the 8-oxo-
dGTPas activity of MTH1 in vitro, fail to induce cancer-specific cell death
66–68
. Intriguingly, 
these compounds did neither increase 8-oxo-G levels nor oxidative stress levels, potentially 
explaining the lack of cellular toxicity. Other studies have reported that small molecule 
inhibitors TH287 and TH588 were able to induce cancer-specific cell death independent from 
MTH1 inhibition, indicating uncharacterized off-target effects
194
. To date, MTH1 is the only 
enzyme known to hydrolyze 8-oxo-dGTP to the corresponding monophosphate
61
. However, 
in addition to inducing DNA damage, it has been reported that 8-oxo-dGTP regulates 
telomere elongation by interacting with telomerase
195
. Depletion of MTH1 could therefore 
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increase telomere dysfunction leading to enhanced cancer-specific cell death. Regarding 
inhibitor specific off target effects, preliminary data indicates that MTH1 inhibitors TH588 
and TH1579 affect microtubule structures in addition to oxidative stress to promote mitotic 
catastrophe and cancer-cell specific death (Gad et al., submitted manuscript).  
In summary, MTH1 biology seems to be more complex than initially thought and further 
characterization of the mechanistic link between MTH1 inhibitors, especially clinical 
candidate Karonudib, and induction of cancer-cell death is required. 
Conclusion Paper I  
In Paper I we obtained supporting data that increased oxidative pressure and deregulated 
hypoxia signaling determine sensitivity to MTH1 inhibition in vitro and in vivo. Resulting 
from malignant transformation, cancer cells commonly display an increased oxidative 
environment, while relying on functional ROS defense systems, including endogenous anti-
oxidants and non-oncogenic addiction enzymes such as MTH1. As the disruption of the 
primary anti-oxidant defense systems for therapeutic purposes is debatable due to the high 
risk of adverse side effects, MTH1 inhibition may offer a promising approach to specifically 
target many different cancer indications either as mono- or combination therapy, by 
selectively killing heterogeneous cancer populations.  
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2.5.2 Paper II 
In Paper II we focused on some of the major challenges that drug discovery against GBM is 
currently facing: extensive tumor heterogeneity, cancer cell plasticity and the presence of 
cancer stem cells
16,75,76
. However, all cancer cells within a glioblastoma can be tracked to a 
common denominator: they arise from neuronal brain cells. In order to fuel ATP intensive 
neuronal activity, the human brain consumes 20 % of the total basal oxygen and 25 % of 
circulating glucose
196,197
. Free oxygen radicals (i.e. superoxide; O2-) and non-radicals 
(i.e. hydrogen peroxide; H2O2) generated as metabolic by-products play essential roles in 
tightly orchestrated redox signaling pathways
198,199
, which are highly sensitive to disruptions. 
Due to the lack of extensive endogenous anti-oxidant defense systems
200,201
, the brain is, 
more than any other tissue, susceptible to oxidative stress, which may lead to 
neurodegeneration and malignant transformation. In this regard, several studies have shown 
that brain cancers, independent of their mutational profile, are characterized by high oxidative 
pressure and a resulting reliance on functional DNA repair and sanitizing enzymes
202–204
. In 
regard to GBM, researchers have identified the amplification of chromosome 7 in 
combination with the loss of chromosome 10 as early genetic events in GBM ontogeny
205,206
. 
Intriguingly, it has been reported that the MTH1-gene is also localized on chromosome 7 
(7p22) and by analyzing three different datasets, we found MTH1 transcripts to be 
significantly overexpressed in GBM. Furthermore, it has been suggested that the expression 
of MTH1 correlates with GBM aggressiveness and proliferative potential
184,202
, thereby 
providing a broad GBM-specific target. Based on this, we hypothesized that MTH1 inhibition 
may present a promising strategy to eliminate heterogeneous GBM populations.  
Initial investigations were performed using a panel of patient-derived GBM cultures
161,207
. 
We found that depletion of functional MTH1 either by siRNA-mediated knockdown or small 
molecule inhibition using MTH1 inhibitors TH588 and TH1579 resulted in decreased 
viability of all GBM cultures, irrespectively of their intrinsic aggressiveness. In line with our 
findings, two other groups provided additional supporting data showing that MTH1 is 
indispensable for GBM growth and survival
184,208
. Next, we aimed to relate the effects of our 
MTH1 inhibitors on GBM cells to oxidized nucleotide sanitation. Indeed, we found 8-oxo-G 
lesions in the DNA of analyzed GBM cultures using a modified comet assay and 
consequently, an increase of general DNA damage upon exposure to TH588 and TH1579. 
Thus, our results are in line with the working model presented by Gad et al.
49
 (Figure 5). In 
addition to its DNA damaging potential, it has been reported that modified guanine 
nucleotides may affect the polymerization of tubulin in vitro and in vivo
209,210
. Since our 
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MTH1 inhibitors induce G2/M arrest and mitotic catastrophe, further studies are currently 
ongoing to investigate potential effects of MTH1 inhibition on tubulin dynamics.  
MTH1 inhibition to overcome GBM heterogeneity 
Heterogeneous GBM populations comprise large numbers of GSCs, which are characterized 
by so called stemness traits including a quiescent state, protection against oxidative stress and 
overexpression of drug efflux pumps, all conferring to GBM aggressiveness and treatment 
resistance. Due to previous observations that our MTH1 inhibitors target GBM cultures 
potently and independent of aggressiveness, we exposed isolated GSCs to MTH1 inhibitors 
TH588 and TH1579 and investigated if they are also dependent on functional MTH1. Indeed, 
we found that depletion of MTH1 resulted in decreased viability and clonogenic potential of 
isolated GSCs. In addition to that, we observed increased incorporation of 8-oxo-dGTP into 
DNA as well as a dramatic prolongation of mitosis and mitotic catastrophe by following 
fluorescently labeled GSCs in real-time. Potential reasons for these MTH1-induced 
phenotypes in GSCs are debatable. Despite the malignant nature and in contrast to normal 
cancer cells, it is generally accepted that cancer stem cells, or in this context GSCs, reside in 
hypoxic niches and exhibit low ROS levels in order to maintain their stemness traits
23,211
. In 
respect to that, several studies have shown that increasing ROS levels in stem cells induces 
differentiation and/or exit of the quiescent state
36,212
. Therefore, it is easy to speculate that 
disrupting ROS defense systems in GSCs i.e. by MTH1 inhibition may lead to increased 
oxidative stress and subsequent exit of the quiescent state, which further promotes the 
accumulation of erroneous nucleotides in the DNA, prolonged mitosis and eventually, mitotic 
catastrophe. In contrast, a different study suggests that GSCs already suffer from higher 
oxidative pressure and reliance to anti-oxidant defense systems compared to non-GSCs
213
, 
which could also explain their addiction to functional MTH1.  
Comparison to standard therapy against GBM 
In addition to treatment resistant GSCs which may promote tumor recurrence, additional 
resistance mechanisms are conferred by an upregulated DSB repair machinery rendering 
GBM insensitive to radiotherapy
78
 and/or the standard chemotherapeutic agent TMZ
214
. 
Pursuing a monotherapy approach, we compared the anti-tumor efficacy of our MTH1 
inhibitors to TMZ and found that TH588 and TH1579 were more potent in eradicating GBM. 
Most importantly, this effect was completely independent of the intrinsic MGMT expression 
levels of tested GBM cultures. Therefore, it is tempting to speculate that MTH1 inhibition 
could be used to target TMZ-resistant or even recurring GBM tumors. As mentioned earlier, 
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it is furthermore plausible that MTH1 inhibitors could be used as radio-sensitizers or in 
combination with radiotherapy
190
. In addition to that, a different study suggests that induction 
of oxidative stress by depletion of glutathione synthesis could sensitize GBM tumors to TMZ 
or Cisplatin
179
. It would be interesting to investigate if oxidative stress mediated by MTH1 
inhibition could sensitize GBM tumors to TMZ therapy.  
Penetration of the blood-brain barrier 
Another major challenge that hampers GBM therapy is the presence of physical barriers such 
as the BBB and the BTB, which separate the circulating blood from the brain and thus, brain 
tumors. The BBB is a semipermeable border formed by endothelial cells, astrocyte end-feet 
and pericytes. Critical substances are retained passively by the selectivity of tight junctions or 
actively through efflux proteins (ATP binding cassette transporter and P-glycoprotein) within 
the BBB
215
. In contrast, the BTB is more complex than the BBB due to aberrant cellular 
compositions of newly developed microvessels
216
. Most drugs penetrate the barriers by 
transmembrane diffusion, a mechanism favored by hydrophobicity and molecular weight
217
. 
Despite the development of several in vitro BBB models
218
, it remains inevitable to determine 
drug penetrance of the BBB in vivo in order to provide reliable predictions on the therapeutic 
outcome. Recently, it has been shown that the zebrafish develops its BBB between day 3 and 
10 post fertilization, while sharing structural and functional similarities with that of 
mammals
219,220
. Supported by these findings, the zebrafish has been introduced as a suitable 
model to investigate BBB penetration, which further increases its clinical relevance.  
In Paper II we applied our orthotopic zebrafish model for GBM to investigate if our MTH1 
inhibitors efficiently target both GBM and GSCs in vivo. Following transplantation, tumor-
bearing zebrafish were swimming freely in TH1579-containing fish water. After an exposure 
of 5 days to TH1579, we found a significant reduction in tumor volume compared to the 
control. Additional in vivo real-time imaging of exposed tumors via light-sheet microscopy 
revealed numerous GBM cells undergoing cell death confirming an overall tumor reduction 
of 25 %, thereby suggesting that MTH1 inhibitor TH1579 is able to reach GBM cells in vivo. 
However, further investigations in higher organisms are necessary to confirm these initial 
results.   
 
 
 
 49 
Conclusion Paper II 
In Paper II we evaluated MTH1 inhibition as a strategy to target heterogeneous GBM 
populations. Irrespectively of the GBM cultures’ intrinsic aggressiveness, the amount of 
GSCs, or MGMT expression levels and thus, resistance mechanisms to the standard therapy 
TMZ, our MTH1 inhibitors TH588 and TH1579 efficiently induced cancer cell death in all 
tested GBM cultures in vitro and in vivo. Further studies to characterize the underlying 
mechanism of action of our clinical candidate Karonudib (TH1579) as well as its BBB-
penetrating ability using higher organisms are currently ongoing. While the anti-tumor 
efficacy of Karonudib as combination therapy in preclinical studies also remains to be 
validated, based on the obtained results, we conclude that MTH1 inhibition indeed represents 
a promising targeted approach to selectively eradicate heterogeneous GBM populations. 
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2.5.3 Paper III  
In the last part of this doctoral thesis, we addressed another major challenge that hampers the 
discovery of potent drugs against GBM: the lack of predictive GBM animal models that are 
suitable for high-throughput drug discovery screens. In the last decade, the zebrafish has 
emerged as a clinically relevant model for all kinds of human malignancies including cancer, 
and orthotopic transplantation of GBM material was found to faithfully recapitulate the 
human disease. Although biological and technical advantages render the zebrafish suitable for 
drug discovery screens, none of the currently available transplantation procedures in 
zebrafish can be used in high-throughput screens
144–146
. Therefore, in Paper III, we aimed to 
refine existing orthotopic zebrafish models for GBM and to develop an approach which 
allows for fully automated high-throughput screens, including automatable tumor 
transplantation, embryo handling, drug exposure and read-out processes. 
Migration potential of transplanted GBM cultures and other cancer types 
As suggested by fate-map analysis and previous data indicating that early zebrafish could 
provide lineage-specific trophic support to human cells
221
, we hypothesized that human GBM 
cells transplanted into the zebrafish blastoderm might migrate into CNS structures of the 
developing zebrafish embryo. Indeed, 24 hours after transplantation we found that the 
majority of transplanted zebrafish embryos developed intracranial tumors. By transplanting 
both patient-derived GBM cultures as well as established GBM cell lines in comparison to 
colorectal cancer lines, we further elucidated that migration behavior into CNS regions was 
GBM specific, but independent from the transplantation site within the blastoderm of the 
zebrafish embryo. This might be due to the fact that ectodermal precursor cells can be found 
at all latitudes in the blastula fate map
222
. 
To further investigate migration potential, we transplanted several other cancer types, 
including different human malignant melanoma lines, prostate and bladder cancer as well as 
non-malignant, immortalized retinal pigmented epithelial (RPE) cells and followed their 
migration behavior in vivo. Transplanted human prostate and bladder cancer lines formed 
tumors alongside intestinal regions of the developing zebrafish embryos, while RPE cells did 
not establish tumors (own unpublished data). In comparison to transplanted GBM cultures 
that migrated deeply into the brain and other CNS regions of developing zebrafish embryos, 
transplanted malignant melanoma lines predominantly formed superficial tumors in the skin 
of the zebrafish tail region (own unpublished data). These observations contradict previous 
study results showing that human metastatic melanoma cells transplanted into blastula stage 
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embryos failed to form tumors in host organs, while non-cancerous melanocytes migrated to 
the normal microenvironment of the skin
221
. One plausible explanation for the lacking tumor 
formation might be the absence of melanoma stem cells or melanoma cells that have 
undergone EMT to promote migration and invasion of the tumor microenvironment or in this 
case, the developing zebrafish embryo
223
. In our case, most of the GBM cultures that were 
transplanted into zebrafish embryos display high levels of invasive GSCs, which can be 
identified by cell surface marker CD133. Already in Paper II, we observed that GBM 
cultures depleted of CD133 positive cells failed to migrate into the CNS to establish a 
congregated tumor. In line with that, here we could show that GBM cells dissociated with 
trypsin, an enzyme degrading surface molecules and potentially depleting GBM cells of 
CD133 significantly reduced their homing capacity to the CNS when compared to 
dissociation with Accutase®, a more gentle dissociation reagent. Based on these results, we 
conclude that surface molecules of transplanted cells could be involved in the perception of 
homing cues and promote migration potential, similarly to cancer cells that have undergone 
EMT to promote invasion and metastasis
223–225
.  
Clinical relevance of zebrafish for drug development against GBM and beyond 
Following the development of a robust orthotopic model for GBM using zebrafish embryos, 
we continued with a detailed characterization to support its clinical relevance. In line with the 
literature
144–146
, we could show that transplanted GBM cells proliferated in vivo leading to 
increased tumor volume, and invaded healthy surrounding brain tissue by developing 
extended tumor microtubules. Moreover, we observed tumor vascularization and interaction 
between the innate immune system of the zebrafish and the transplant. Thus, our model 
faithfully recapitulates the human disease in vivo and opens numerous avenues for drug 
discovery by targeting GBM cells directly or interfering with tumor vascularization or the 
innate immune system to inhibit tumor growth.  
As briefly mentioned in the previous section, the zebrafish has been introduced as a suitable 
model to investigate BBB penetration, which is clearly of outmost importance when it comes 
to GBM drug discovery. In this regard, several studies could show that the BBB in zebrafish 
displays structural and functional similarities to that of mammals
219,220,226
 as it starts to 
develop around day 3 post fertilization. Therefore, evaluating the anti-tumor efficacy of 
selected drugs against GBM using our orthotopic model and the suggested experimental set-
up (Figure 12), ultimately provides information regarding the drug’s ability to penetrate the 
BBB. In Paper III we applied our orthotopic GBM model to test the anti-tumor efficacy of 
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selected TKIs, which are currently in clinical studies, on TMZ-resistant GBM cultures. Only 
Erlotinib displayed superior anti-tumor effects compared to other tested TKIs, indicating 
sufficient BBB passage. Our findings are in line with other studies showing that Erlotinib has 
the best BBB penetrance and lowest brain efflux rate of our tested TKIs in humans
227–230
, 
while inducing the highest response rate in patients. This indicates that our orthotopic model 
for GBM exhibits enormous predictive value by faithfully recapitulating the in vivo 
pharmacology of clinically tested drugs.  
Besides high conservation of numerous drug targets and physiological processes, as 
thoroughly elaborated on in the introduction, it is postulated that drug metabolism and 
pharmacology also display a close correlation between zebrafish and humans
120,231
. Several 
human drugs have been screened for conserved effects in zebrafish, i.e. drugs that induce 
repolarization cardiotoxicity or modulate cardiac contractility and vasomotion
150,232
.  Notably, 
the majority of effects in humans were recapitulated in zebrafish. Additionally, around 80 % 
of compounds discovered in diverse zebrafish screens evoked a similar response in rodents
120
. 
Due to the high probability of direct correlation between effects in zebrafish and humans, but 
also zebrafish and rodents, it is likely that drug distribution, metabolism and excretion are 
highly conserved among these species. Recently, a research group has reported that many 
human cytochrome P450 (CYP) enzymes possess direct orthologues in zebrafish
231
, 
providing first indications that metabolism is indeed highly conserved between zebrafish and 
humans.  
Although further studies are required to fully understand all in vivo pharmacology – essential 
ADME (administration, distribution, metabolism, and excretion) parameters in aquatic model 
systems, the number of compound screens
120
 as well as the number of discovered compounds 
using zebrafish is steadily increasing
233,234
. In a landmark study published in 2007, Professor 
Zon and his research group performing zebrafish drug screens identified a stabilized derivate 
of prostaglandin E2 (PGE2), also known as Prohema, which improves the engraftment of 
transplanted umbilical cord blood cells by enhancing the homing effect to the bone 
marrow
235
. Notably, Prohema was the first drug identified in zebrafish, which was 
subsequently recommended for clinical evaluation. After passing clinical phase I in 2013, 
Prohema is currently tested in clinical phase II. Besides facilitating the discovery of novel 
drugs, drug discovery screens using zebrafish may furthermore accelerate studies that focus 
on new drug combinations and the repurposing of existing drugs
236
 in order to improve the 
life of many patients. 
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Conclusion Paper III  
In Paper III, we developed an improved orthotopic zebrafish model for GBM, which 
faithfully recapitulates the clinical characteristics of GBM tumors in vivo. In contrast to 
currently existing orthotopic zebrafish models for GBM, it does not require technically 
challenging intracranial transplantations, and can directly be implemented in fully automated 
high-throughput drug screens, including automatable tumor transplantation, embryo handling, 
drug exposure and read-out processes. Most importantly, as a robust and predictive drug 
screen using our model can be performed in zebrafish embryos younger than 5 days, no 
ethical permit is required in most countries. Moreover, the application of our model as a 
useful tool and complementary animal system could decrease the number of drugs that need 
to be tested in higher organisms. Due to these benefits, our orthotopic zebrafish model for 
GBM complies with the 3R guidelines for animal research, namely replace, reduce and 
refine, and offers great potential to 1) identify and optimize novel effective drugs against 
GBM, and potentially, other cancer indications 2) accelerate repurposing of already existing 
drugs and 3) facilitate screening for tailor-made drugs, as a step towards personalized 
medicine. 
 
 
 
 
 
 
 
 
 
 
 
 
54 
2.6 CONCLUSION AND FUTURE PERSPECTIVE 
Cancer drug discovery is hampered by the complex and dynamic nature of cancer including 
constant alterations in molecular and cellular interactions, activation of cancer resistance 
mechanisms, as well as ineffective drug delivery systems and life-threatening side-effects. 
Drug discovery against GBM is particularly challenged by extensive tumor heterogeneity, the 
presence of physical barriers such as the BBB and the lack of orthotopic animal models, 
ideally suitable for high-throughput drug screens.  
In the first part of this doctoral thesis, we have addressed these challenges by pursuing a 
targeted therapy approach focusing on deregulated redox systems, representing a cancer cell’s 
Achilles’ heel. For this, we have combined established biochemical and cellular assays with 
the broadly applicable zebrafish model (Figure 14).  
 
 
Figure 14: Illustration of strategic research approach 
Although novel effective therapeutic options against GBM are urgently needed, drug discovery is severely 
challenged by extensive tumor heterogeneity, the presence of physical barriers such as the BBB and the lack of 
orthotopic animal models suitable for high-throughput drug screens. In this doctoral thesis, we have addressed 
these challenges by pursuing a targeted therapy approach focusing on deregulated redox systems, representing a 
cancer cell’s Achilles’ heel, and evaluating MTH1 as a potential target in heterogeneous GBM populations. 
Moreover, we developed a clinically relevant in vivo model using zebrafish to facilitate high-throughput drug 
screens.  
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Following the introduction of MTH1 as a promising anti-cancer target, in Paper I, we aimed 
to characterize factors rendering cancer cells to MTH1 inhibition. We found that increased 
oxidative pressure and deregulated hypoxia signaling determine sensitivity to MTH1 
inhibition in vitro and in vivo. As cancer cells commonly display an increased oxidative 
environment, enhancing their reliance on functional ROS defense systems, MTH1 inhibition 
may offer a promising approach to specifically target many different cancer indications either 
as mono- or combination therapy, by selectively killing heterogeneous cancer populations.  
In Paper II we tested this hypothesis by validating MTH1 inhibition as a strategy to target 
heterogeneous GBM populations. Indeed, we found that our MTH1 inhibitors TH588 and 
TH1579 efficiently induced cancer cell death in all tested GBM cultures, independent of 
intrinsic aggressiveness, heterogeneity or resistance mechanisms to the standard therapy 
TMZ, both in vitro and in vivo. With this, we have provided supporting evidence that MTH1 
inhibition may indeed represent a promising targeted approach to selectively eradicate 
heterogeneous GBM populations. 
However, future preclinical studies including further characterization of the mode of action of 
our MTH1 inhibitors, especially of the clinical candidate Karonudib (TH1579), and in vivo 
studies confirming its BBB-penetrating ability using higher organisms are needed. In addition 
to that, it is important to identify potential resistance mechanism to MTH1 inhibition as early 
as possible to successfully overcome them, possibly by enhancing anti-tumor efficacy of 
Karonudib as part of a combination therapy. 
To address the urgent need of an animal model suitable for high-throughput drug screens, in 
Paper III, we developed an orthotopic zebrafish model for GBM, which faithfully 
recapitulates the clinical characteristics of GBM tumors in vivo. Performing a novel 
transplantation technique using blastula stage zebrafish embryos, our model can directly be 
implemented in fully automated high-throughput drug screens, including automatable tumor 
transplantation, embryo handling, drug exposure and read-out processes. Within 5 days, a 
robust and predictive drug screen can be performed to identify and optimize novel anti-GBM 
drugs, accelerate repurposing of already existing drugs, as well as to determine effective drug 
combinations with low systemic toxicity. 
Moreover, due to its clinical relevance, our orthotopic zebrafish model allows for 
implementation in precision oncology platforms alongside other clinical applications to 
improve identification of tailor-made therapies. Freshly excised tumor specimen from 
patients could be transplanted into zebrafish using automated injection robotics, generating 
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individual zebrafish avatar libraries to screen for the most effective treatment for the 
corresponding cancer patient. The future is now: in September 2018, a co-clinical study using 
zebrafish embryos was launched by the University of Pisa (ClinicalTrials.gov Identifier: 
NCT03668418). This study combines an observational trial on patients operated on hepato-
biliar-pancreatic or gastro-intestinal cancer undergoing chemotherapeutic treatment with an 
animal trial using zebrafish embryos transplanted with patient cancer cells to demonstrate the 
zebrafish model’s ability to predict the most effective treatment option for each patient. This 
co-clinical study and our orthotopic zebrafish model for GBM presented in Paper III raise 
high hopes for personalized GBM medicine and beyond.  
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